Drug solution administration device
Patent Information
- Application Number
- JP2024507610
- Authority / Receiving Office
- JP · JP
- Patent Type
- Applications
- Priority Date
- 2023-02-16
- Filing Date
- 2023-02-16
- Publication Date
- 2024-11-21
AI Technical Summary
Conventional liquid drug administration devices require users to manually remove a cap to connect the needle and cartridge, which can be cumbersome and difficult, leading to inconsistent puncturing and administration processes.
A liquid drug administration device featuring a double-ended needle with a locking mechanism that automatically connects to a syringe upon puncturing, allowing the plunger to push a gasket into the barrel, ensuring continuous drug administration without manual intervention.
Facilitates easy and reliable connection of the double-ended needle to the syringe during puncturing, enabling automatic and continuous drug administration, reducing user effort and improving the reliability of the process.
Abstract
Description
Medical solution administration device
[0001] The present invention relates to a medicinal liquid administration device that administers a medicinal liquid to a puncture target that has been punctured with a double-ended needle.
[0002] Portable drug solution administration devices for puncturing the skin of a patient to administer a drug solution for subcutaneous injection have been known. The drug solution administration device disclosed in JP 2018-535042 A has a cylindrical main body to which a cap is attached in the distal direction, and the main body contains a cartridge filled with the drug solution and a needle holder holding a needle. The needle and needle holder are disposed distally relative to the cartridge. The needle protrudes distally and proximally relative to the needle holder.
[0003] When administering a medicinal liquid using the medicinal liquid administration device, the user rotates the cap relative to the main body and removes it. The resilience of the spring in the cap urges the needle along with the needle holder toward the cartridge. As the needle holder moves toward the cartridge, the proximal end of the needle is inserted into the cartridge. This allows the medicinal liquid in the cartridge to be administered through the needle.
[0004] In the drug solution administration device of JP2018-535042A, the user must remove the cap from the main body before performing the puncture operation, and the removal of the cap triggers the connection between the needle and the cartridge. However, it is cumbersome for the user to remove the cap when performing the puncture operation, and it is also expected that the user may find it difficult to remove the cap.
[0005] The present invention aims to solve the above-mentioned problems.
[0006] an aspect of the present invention is a drug solution administration device comprising: a housing formed in a hollow cylindrical shape; a syringe housed in the housing, the syringe having a barrel with a drug chamber filled with a drug solution and a gasket that is liquid-tight and slidable inside the barrel; a plunger that is biased in a distal direction by a biasing member; a double-ended needle that is disposed inside the housing and has a first needle portion that protrudes in the distal direction to puncture a target to be punctured and a second needle portion that protrudes in a proximal direction toward the syringe, the double-ended needle having an inner cavity of the first needle portion and an inner cavity of the second needle portion that communicates; a hollow cylindrical needle cover that has a distal opening, at least a portion of which is disposed inside the housing, covers the first needle portion in an initial state, and is pressed against the target to be punctured so as to be displaced relative to the housing in the proximal direction, causing the first needle portion to protrude from the distal opening; and a locking mechanism that prevents the plunger from moving in the distal direction in an initial state, As the needle cover moves toward the base end, the locking mechanism releases the plunger from its movement prevention block, and the plunger, biased by the biasing member, pushes the gasket toward the tip, causing the syringe to move toward the tip, the second needle portion puncturing the tip of the syringe and connecting the second needle portion to the chamber of the barrel, and as the second needle portion punctures the tip of the syringe, the gasket moves toward the tip relative to the barrel.
[0007] According to the present invention, when the user presses the tip of the needle cover against the target to be punctured, the plunger moves the syringe toward the tip, puncturing the double-ended needle into the tip of the syringe and moving the gasket toward the tip within the barrel chamber. The double-ended needle and syringe are automatically connected and the medicinal solution is administered automatically and continuously in conjunction with the puncturing operation by the user. Because the double-ended needle and syringe are automatically connected in conjunction with the puncturing operation, the user does not need to perform the connecting operation between the double-ended needle and syringe, and the double-ended needle and syringe can be connected simply and reliably.
[0008] 1. An external perspective view of a drug solution administration system according to a first configuration. An exploded perspective view of the drug solution administration system shown in FIG. 1. An external perspective view of a drug solution administration device in the drug solution administration system of FIG. 1. An exploded perspective view of the drug solution administration device shown in FIG. 3. A cross-sectional view taken along line V-V in FIG. 3. An enlarged cross-sectional view showing the vicinity of the base end of the drug solution administration device of FIG. 5. A cross-sectional view taken along line VII-VII in FIG. 3. An enlarged cross-sectional view showing the vicinity of the base end of the drug solution administration device of FIG. 7. An enlarged cross-sectional view showing the vicinity of the tip of the drug solution administration device of FIG. 5. An external perspective view of a needle cover and a syringe unit constituting the drug solution administration device. An external perspective view of the syringe unit shown in FIG. 10. An exploded perspective view of the syringe unit shown in FIG. 11. An overall front view of the syringe unit shown in FIG. 12. A plan view of the syringe holder shown in FIG. 13 as seen from the base end side. A plan view of the syringe holder shown in FIG. 13 as seen from the tip side. An enlarged front view of the vicinity of the tip of the syringe holder shown in FIG. 13. A cross-sectional view taken along line XVII-XVII in FIG. 16. A cross-sectional view taken along line XVIII-XVIII in FIG. 17. 26. An enlarged perspective view showing the vicinity of the tip of a syringe unit according to a modified example. A cross-sectional view taken along line XX-XX of FIG. 19. FIG. 21 is a plan view of the needle hub as viewed from the base end side. A cross-sectional view taken along line XXII-XXII of FIG. 5. A cross-sectional view taken along line XXIII-XXIII of FIG. 5. An exploded perspective view of a drive unit in a drug solution administration device. An exploded perspective view of a locking member and a lock body in the drive unit of FIG. 24. A cross-sectional view of the drug solution administration system taken along line XXVI-XXVI of FIG. 1. A cross-sectional view taken along line XXVII-XXVII of FIG. 26. An overall cross-sectional view showing a state in which the needle cover of the drug solution administration device of FIG. 5 is pressed against the skin and punctured. An enlarged cross-sectional view showing the vicinity of the base end of the drug solution administration device shown in FIG. 28. An overall cross-sectional view showing another cross-section of the drug solution administration device of FIG. 28. An overall cross-sectional view showing a state in which the connection between the syringe and the double-ended needle of the drug solution administration device has been completed. An enlarged cross-sectional view showing the vicinity of the tip of the drug solution administration device of FIG. 31. An overall cross-sectional view showing a state in which the gasket has moved within the barrel and drug solution administration has been completed. 10 is a general cross-sectional view showing a state in which a fixed amount of medicinal liquid is administered using a plunger according to a modified example. FIG. 11 is a general cross-sectional view showing a state in which a double-ended needle is covered by a needle cover of a medicinal liquid administration device.36A is an enlarged cross-sectional view of the vicinity of the base end showing the movement of the locking member toward the distal end when the drug solution administration device is separated from the skin after drug solution administration has been completed, and FIG. 36B is an enlarged cross-sectional view showing a state in which the locking member shown in FIG. 36A has moved and the engagement arm has elastically deformed radially inward. An enlarged cross-sectional view showing the vicinity of the base end of the drug solution administration device of FIG. 35. An overall cross-sectional view showing another cross-section of the drug solution administration device of FIG. 37. An overall cross-sectional view of a drug solution administration system according to a second configuration. An enlarged cross-sectional view showing the vicinity of the distal end of the drug solution administration device. An enlarged cross-sectional view showing a puncturing completion state in which the first needle part of the drug solution puncturing device has been punctured and the first bacteria-shielding cover has been folded. An enlarged cross-sectional view showing a state in which the first and second bacteria-shielding covers have been folded and the double-ended needle and the syringe are connected. FIG. 43A is a schematic diagram showing a first sterilization apparatus for sterilizing a needle unit using a first sterilization method, and FIG. 43B is a schematic diagram showing a second sterilization apparatus for sterilizing a syringe using a second sterilization method. 46A is a partial cross-sectional front view of the first germ-shielding cover, and FIG. 46B is a partial cross-sectional front view of the second germ-shielding cover. 46B is an enlarged cross-sectional view of the drug solution administration device shown in FIG. 45, showing a puncture state in which the first germ-shielding cover is folded and the first needle part is punctured. 47 is an enlarged cross-sectional view of the drug solution administration device shown in FIG. 47, showing a connection completion state in which the second germ-shielding cover is folded and the double-ended needle and the syringe are connected. 48 is an overall cross-sectional view of the drug solution administration system according to the fourth configuration. 49 is an external perspective view of the syringe holder in the drug solution administration device of FIG. 49. 50 is an enlarged front view showing the vicinity of the tip of the syringe holder of FIG. 50. 51 is a cross-sectional view taken along line LII-LII in FIG. 51. 52 is a cross-sectional view taken along line LIII-LIII in FIG. 52. 53 is a cross-sectional view taken along line LIV-LIV in FIG. 49. Figures 55A to 55C are enlarged explanatory views of the operation, showing the process in which the first guide rib is inserted into the first guide groove and the syringe unit is decelerated by the deceleration mechanism. Figure ...Fig. 62 is an overall cross-sectional view showing the puncturing state of the drug solution administration device of Fig. 57. Fig. 63 is an enlarged cross-sectional view showing the vicinity of the needle hub of the drug solution puncturing device of Fig. 60. Fig. 64 is an overall cross-sectional view showing the drug solution administration state by the drug solution administration device of Fig. 60. Fig. 65 is an enlarged cross-sectional view showing the vicinity of the needle hub of the drug solution puncturing device of Fig. 62.
[0009] The chemical solution administration system 10A will be described with reference to Figures 1 to 38. As shown in Figures 1 and 2, the chemical solution administration system 10A includes a chemical solution administration device 12A and a packaging container 14 that houses the chemical solution administration device 12A.
[0010] 3 to 9 , the drug solution administration device 12A includes a hollow cylindrical housing 16, a needle cover 18A movably housed within the housing 16, a syringe unit 20A housed within the housing 16, a needle unit 26A including a double-ended needle 22 and a needle hub 24A, a guide mechanism 28 that guides the syringe unit 20A toward the distal end, and a drive unit 34 having a locking mechanism 32 that prevents a plunger 30 from moving toward the distal end in an initial state before a puncture operation is performed by a user.
[0011] The housing 16 is formed into a cylindrical shape from a resin material. When viewed in the axial direction, the cross section of the housing 16 is elliptical (see FIG. 3). The housing 16 has a cylindrical body 36 extending along the axial direction (the direction of arrows A and B) and an end cap 38 closing the base end of the cylindrical body 36.
[0012] The cylindrical body 36 has a predetermined length in the axial direction (direction of arrows A and B). The distal end and proximal end of the cylindrical body 36 are each open. The peripheral wall of the cylindrical body 36 is provided with an observation window 40 and a hole 42. The observation window 40 penetrates the peripheral wall of the cylindrical body 36, allowing the syringe 68 housed inside the cylindrical body 36 to be viewed from the outside.
[0013] The holes 42 are arranged near the base end of the cylindrical body 36 (in the direction of arrow A), and are provided as a pair spaced apart along the peripheral wall of the cylindrical body 36, and penetrate through to the interior of the cylindrical body 36.
[0014] 3 to 5, the peripheral wall of the cylindrical body 36 is provided with first to third engagement holes 44a, 44b, and 44c. The first to third engagement holes 44a, 44b, and 44c are provided at positions spaced apart from each other by approximately 90° in the circumferential direction relative to the opening direction of the confirmation window 40. The first to third engagement holes 44a, 44b, and 44c each penetrate the peripheral wall of the cylindrical body 36.
[0015] The pair of first engagement holes 44a are positioned further distally (in the direction of arrow B) than the confirmation window 40, and are positioned symmetrically about the axial center of the cylindrical body 36. First engagement portions 46a of the needle hub 24A housed inside the cylindrical body 36 are engaged with the first engagement holes 44a (see FIG. 5).
[0016] The pair of second engagement holes 44b are disposed proximal to the confirmation window 40 (in the direction of arrow A) and are disposed symmetrically about the axial center of the cylindrical body 36. Second engagement portions 46b of a syringe holder 70A housed inside the cylindrical body 36 can engage with the second engagement holes 44b (see FIG. 5).
[0017] The pair of third engagement holes 44c are positioned further proximal (in the direction of arrow A) than the second engagement holes 44b, and are positioned symmetrically about the axial center of the cylindrical body 36. The third engagement holes 44c are engaged with third engagement portions 46c of the end cap 38 attached to the proximal end of the cylindrical body 36 (see FIG. 5).
[0018] 5 to 8, the end cap 38 has a lid portion 48 that closes the base end of the cylindrical body 36, a pressing portion 50 that extends from the outer edge of the lid portion 48 toward the tip (in the direction of arrow B), a holding cylindrical portion 52 that is disposed radially inside the pressing portion 50 and protrudes toward the tip from the lid portion 48, and a shaft portion 54 that extends toward the tip from the center of the lid portion 48. The lid portion 48 is disk-shaped and closes the open base end of the cylindrical body 36.
[0019] 6, the retaining tube portion 52 is cylindrical and opens toward the tip end, and has a plurality of engaging protrusions 56 that protrude radially outward on the outer peripheral surface of the tip end. The engaging protrusions 56 are spaced apart from one another along the circumferential direction of the outer peripheral surface of the retaining tube portion 52. The engaging protrusions 56 are engaged with a lock body 156, which will be described later.
[0020] The retaining portion 50 is formed in an annular shape and protrudes toward the tip (in the direction of arrow B) from the end face on the tip side of the lid portion 48. The outer peripheral surface of the retaining portion 50 is provided with a pair of third engagement portions 46c that protrude radially outward. The third engagement portions 46c have a protruding shape that protrudes from the outer peripheral surface.
[0021] The proximal end of the syringe unit 20A comes into contact with the distal end of the pressing portion 50, thereby preventing the syringe unit 20A from moving in the proximal end direction (direction of arrow A).
[0022] The shaft portion 54 has an axial shape that protrudes distally from the distal end surface of the lid portion 48. The shaft portion 54 is disposed on the axis of the housing 16. The shaft portion 54 is housed inside the cylindrical body 36, a lock body 156 (described later), and the syringe unit 20A, and extends to near the axial center of the cylindrical body 36 (see FIG. 5 ).
[0023] The shaft portion 54 is inserted through an injection spring (biasing member) 146 and a plunger 30 that constitute a drive unit 34 (described later).
[0024] When the end cap 38 is attached to the base end of the cylindrical body 36, the third engagement portion 46c engages with the third engagement hole 44c of the housing 16, fixing the end cap 38 to the housing 16, and the open base end is closed by the lid portion 48, with the shaft portion 54 positioned on the axis of the cylindrical body 36.
[0025] 5 and 9, needle cover 18A is formed in a hollow cylindrical shape and is provided at the tip of housing 16, with at least a portion of it being provided inside cylindrical body 36 of housing 16. Needle cover 18A is movable in the axial direction relative to housing 16. In the initial state shown in FIGS. 5, 7 and 9, before the user performs a puncture operation, needle cover 18A covers at least first needle portion 112 of needle unit 26A, which will be described later.
[0026] As shown in Figures 4 and 5, the needle cover 18A comprises a cylindrical main body portion 58 provided at the tip, a cover portion 60 extending from the main body portion 58 toward the base end (in the direction of arrow A), and a pair of extension portions 62 extending from the base end of the cover portion 60.
[0027] A distal opening 64 that penetrates in the axial direction is provided at the center of the distal end of the main body 58. When the needle cover 18A is pressed against the user's skin S during a puncture operation, the needle cover 18A moves relative to the housing 16 in the proximal direction (direction of arrow A), and the first needle 112 of the needle unit 26A is inserted through the distal opening 64 and protrudes from the needle cover 18A in the distal direction (direction of arrow B).
[0028] 4 and 10 , the cover portion 60 has a pair of slits 66. The slits 66 extend from the base end of the cover portion 60 toward the tip end and are arranged symmetrically about the axis of the needle cover 18A. The slits 66 open at the base end of the cover portion 60. As shown in FIG. 10 , when the syringe unit 20A is housed inside the needle cover 18A, the pair of holder protrusions 102 of the syringe holder 70A can be inserted into the slits 66, respectively.
[0029] The extension portion 62 extends from the base end of the cover portion 60 in the base end direction (direction of arrow A) and is disposed along the circumferential direction of the needle cover 18A at a position approximately 90° away from the slit 66. When the needle cover 18A moves relative to the housing 16 in the base end direction (direction of arrow A), the base end of the extension portion 62 abuts against the tip of a locking member 152 of the drive unit 34 (described later), pushing the locking member 152 in the base end direction.
[0030] As shown in Figures 11 and 12, syringe unit 20A has a syringe 68 and a syringe holder 70A that is provided on the outer periphery of syringe 68 and holds syringe 68, and is housed inside housing 16 and is movable along the tip direction (direction of arrow B) (see Figure 5).
[0031] 5 and 7, the syringe 68 includes a barrel 74 having a chamber 72 filled with a medicinal solution M, a gasket 76 that is slidable liquid-tightly inside the barrel 74, and a cap 78 that is attached to the tip of the barrel 74. The base end of the barrel 74 has a flange 80 that extends radially outward from the barrel 74.
[0032] The syringe 68 has a nozzle 82 (see FIG. 9) that is disposed at the tip of the barrel 74 and has a diameter smaller than that of the barrel 74, and a cap 78 is attached to the outer periphery of the nozzle 82. As a result, the outer periphery of the nozzle 82 is covered by the cap 78. A nozzle hole 84 opens at the tip of the nozzle 82.
[0033] 9 , the cap 78 is formed into a cylindrical shape that is smaller in diameter and shorter in the axial direction than the syringe 68. The cap 78 includes a large-diameter portion 86 located at the base end and a small-diameter portion 88 located at the tip of the large-diameter portion 86 and having a smaller diameter than the large-diameter portion 86, and has a step portion 90 at the boundary between the large-diameter portion 86 and the small-diameter portion 88. The step portion 90 has a surface that extends in the radial direction perpendicular to the axis of the cap 78. Because the cap 78 is formed to have a smaller diameter and be shorter in the axial direction than the barrel 74 of the syringe 68, for example, when the syringe 68 is sterilized by heat, the amount of deformation of the cap 78 due to the heat is smaller than the amount of deformation of the syringe 68.
[0034] The tip of the small diameter portion 88 has an insertion hole 92 through which the second needle portion 114 of the double-ended needle 22 can be inserted. The insertion hole 92 faces the nozzle hole 84 of the syringe 68 and communicates with it. The tip of the insertion hole 92 has a trapezoidal cross section that widens toward the tip. A lid 94 is provided between the inner surface of the tip of the small diameter portion 88 and the inner surface of the tip of the cap 78. The insertion hole 92 and the nozzle hole 84 face each other via the lid 94. The lid 94 is a disk-shaped member made of an elastic material and has a constant thickness. The lid 94 faces the insertion hole 92 and is sandwiched between the inner surface of the tip of the small diameter portion 88 and the inner surface of the tip of the cap 78.
[0035] As shown in Figures 11 and 12, syringe holder 70A has a cylindrical holder body 96, a flange accommodating portion 98 formed at the base end of holder body 96, and a holder tip tube portion 100 extending from the tip of holder body 96 in the tip direction (direction of arrow B), and syringe holder 70A is arranged inside housing 16 so as to be movable in the tip direction (direction of arrow B).
[0036] The holder body 96 extends along the axial direction, and the barrel 74 is housed inside the holder body 96. Because the syringe 68 may be deformed and curved due to heat applied during autoclave sterilization or the like, a clearance is provided between the holder body 96 and the barrel 74 to allow for such deformation (see FIG. 5 ). The outer peripheral surface of the holder body 96 has a pair of holder protrusions 102. The holder protrusions 102 protrude radially outward from the outer peripheral surface of the holder body 96 and extend along the axial direction. The pair of holder protrusions 102 are arranged symmetrically about the axis of the syringe holder 70A.
[0037] When the syringe unit 20A is housed inside the needle cover 18A, the holder protrusions 102 of the syringe holder 70A are inserted into the slits 66 (see FIG. 10).
[0038] Holder protrusion 102 includes second engagement portion (engagement portion) 46b. Second engagement portion 46b protrudes in a direction perpendicular to the extension direction of holder protrusion 102. When syringe holder 70A is housed inside housing 16, second engagement portion 46b engages with second engagement hole 44b of housing 16. In an initial state before a puncture operation is performed by the user, second engagement portion 46b engages with second engagement hole 44b, thereby holding syringe unit 20A including syringe holder 70A in housing 16 (see FIGS. 5 and 6 ).
[0039] 11 to 14, the flange accommodating portion 98 is formed in a generally oval shape corresponding to the flange 80 of the syringe 68, and has a recessed shape recessed from the base end of the syringe holder 70A. The flange 80 of the syringe 68 is accommodated inside the flange accommodating portion 98. By accommodating the flange 80 of the syringe 68 in the flange accommodating portion 98, the syringe 68 is positioned and held in the distal direction relative to the syringe holder 70A.
[0040] The flange accommodating portion 98 has a pair of curved portions 104 protruding in the proximal direction on the outside thereof, and the curved portions 104 form the outer edge of the flange accommodating portion 98 and have a curved shape that is convex radially outward. A proximal end support guide 140 of the guide mechanism 28, which will be described later, is disposed on the outer peripheral surface of the curved portions 104. The proximal end of the holder protrusion 102 extends to the proximal end of the curved portions 104 and forms a part of the proximal end support guide 140.
[0041] 11 to 13, the holder tip tube portion 100 is cylindrical and has a smaller diameter than the holder body portion 96. The nozzle 82 and cap 78 of the syringe 68 are housed inside the holder tip tube portion 100. The holder tip tube portion 100 is disposed so as to surround the nozzle 82 and cap 78 of the syringe 68 (see FIG. 9). The holder tip tube portion 100 is inserted into the guide tube portion 118 of the needle hub 24A.
[0042] As shown in Figures 13, 15 and 16, the holder tip tube portion 100 includes a holding portion 106 that elastically biases the cap 78 radially inward, and a tip slide guide 130 (described later) that guides the cap 78 when it is inserted into the guide tube portion 118 of the needle hub 24A.
[0043] The holding portion 106 elastically biases the tip end of the syringe 68 radially inward via the cap 78. The holding portion 106 has multiple flexible arms 108 that press the outer peripheral surface of the cap 78 radially inward at multiple circumferential locations. The multiple flexible arms 108 are disposed in an opening 110 that opens at the base end of the holder tip tube portion 100, and protrude from the tip of the holder body portion 96 in the distal direction (direction of arrow B) at the opening 110. The inner peripheral surfaces (radially inner ends) of the flexible arms 108 abut against the outer peripheral surface of the small diameter portion 88 of the cap 78 (see FIGS. 17 and 18 ).
[0044] The multiple flexible arms 108 are arranged at equal intervals along the circumferential direction of the syringe holder 70A. The multiple flexible arms 108 press the cap 78 of the syringe 68 radially inward at multiple locations along the circumferential direction, thereby coaxially holding the nozzle 82 (cap 78) at the tip of the syringe 68 with respect to the holder tip tube portion 100 at the tip of the syringe holder 70A. The number of flexible arms 108 is preferably at least three.
[0045] The cap 78 pressed by the flexible arm 108 has a small diameter and is short in the axial direction compared to the barrel 74. Therefore, when heat is applied to the syringe 68 during autoclave sterilization, for example, the amount of deformation of the cap 78 is smaller than the amount of deformation of the barrel 74 caused by the heat. Therefore, by holding the cap 78 with the flexible arm 108, the tip of the syringe 68 can be held coaxially with the syringe holder 70A with higher precision via the cap 78.
[0046] As shown in FIG. 18, the flexible arms 108 press the small diameter portion 88 of the cap 78 in the radial direction.
[0047] For example, a syringe holder 70a having a holding portion 106a according to a modified example shown in Figures 19 and 20 may be employed. The holding portion 106a of the syringe holder 70a has a plurality of flexible arms 108a that press the outer peripheral surface of the cap 78 radially inward at a plurality of circumferential locations.
[0048] The multiple flexible arms 108a are arranged in the opening 110 of the holder tip tube portion 100, and protrude from the opening tip of the opening 110 toward the base end (direction of arrow A), and the inner surfaces (radial inner ends) of the flexible arms 108a abut against the outer surface of the small diameter portion 88 in the cap 78.
[0049] The multiple flexible arms 108a are arranged at equal intervals from one another along the circumferential direction of the syringe holder 70a. The multiple flexible arms 108a press the cap 78 of the syringe 68 radially inward, thereby coaxially holding the nozzle 82 (cap 78) at the tip end of the syringe 68 with respect to the holder tip tube portion 100 at the tip end of the syringe holder 70a. The multiple flexible arms 108a press the small diameter portion 88 of the cap 78 and engage with the tip side of the stepped portion 90 of the cap 78.
[0050] The contact area between the inner peripheral surface of flexible arm 108a and the outer peripheral surface of cap 78 is larger than the contact area between flexible arm 108 of syringe holder 70A and cap 78. Therefore, by bringing multiple flexible arms 108a into surface contact with the outer peripheral surface of cap 78 over a larger area and pressing it radially inward, it is possible to hold cap 78 (nozzle 82) coaxially at the tip of syringe holder 70a.
[0051] As shown in Figures 5 and 9, needle unit 26A includes a double-ended needle 22 having first and second needle portions 112, 114, and a needle hub 24A having a support portion 124 that supports the double-ended needle 22, and is disposed inside housing 16 in the direction of the tip of syringe unit 20A (in the direction of arrow B).
[0052] The double-ended needle 22 has a first needle portion 112 that protrudes distally from a support portion 124 to puncture the skin S, and a second needle portion 114 that protrudes proximally from the support portion 124, and is fixed to the support portion 124 of the needle hub 24A by adhesive or the like. The inner cavity 112a of the first needle portion 112 and the inner cavity 114a of the second needle portion 114 are in communication with each other.
[0053] The needle hub 24A comprises a hub body 116 held in the housing 16 and a guide tube portion 118 provided at the tip of the hub body 116, and the tip of the syringe unit 20A can be inserted into the interior of the needle hub 24A from the base end toward the tip.
[0054] The hub body 116 is formed in a cylindrical shape with an open base end, and is provided with a pair of resiliently tiltable arms 120 on the outer peripheral surface of the hub body 116. The distal ends of the arms 120 are fixed ends connected to the outer peripheral surface of the hub body 116, and extend from the distal ends toward the proximal ends. The proximal ends of the arms 120, which are movable ends, are provided with first engagement portions 46a that protrude outward. When the needle hub 24A is housed inside the housing 16 and the first engagement portions 46a engage with the first engagement holes 44a, the needle hub 24A is held at the distal ends of the cylindrical portions of the housing 16 (see FIG. 9 ).
[0055] A cover spring 122 is disposed between the hub body 116 and the needle cover 18A. The cover spring 122 is a resilient member formed of a coil spring. The base end of the cover spring 122 engages with the distal end of the hub body 116. The distal end of the cover spring 122 engages with the inner distal end surface of the main body 58 of the needle cover 18A. The resilient force of the cover spring 122 biases the needle cover 18A to move relative to the housing 16 and the needle hub 24A in the distal direction (direction of arrow B).
[0056] The guide tube portion 118 is a cylindrical member with a bottom and a support portion 124 at its tip, surrounds the second needle portion 114, and allows the holder tip tube portion 100 of the syringe holder 70A to be inserted therein. The tip of the guide tube portion 118 is provided with the support portion 124 that supports the double-ended needle 22. The support portion 124 is perpendicular to the axial direction of the needle hub 24A, and the double-ended needle 22 is supported at the center of the support portion 124 by adhesive or the like. The first needle portion 112 is disposed outside (toward the tip) of the guide tube portion 118. That is, the first needle portion 112 and the second needle portion 114 of the double-ended needle 22 protrude in opposite directions with the support portion 124 between them.
[0057] After the syringe unit 20A moves toward the distal end, the holder tip tube portion 100 is inserted into the guide tube portion 118, and the second needle portion 114 punctures the lid body 94, the tip of the cap 78 held by the holder tip tube portion 100 abuts against the support portion 124. This locks the syringe unit 20A, and the movement of the syringe unit 20A toward the distal end is stopped (see FIGS. 31 and 32). The support portion 124 of the guide tube portion 118 functions as a stopper that can prevent the syringe unit 20A from moving toward the distal end after the second needle portion 114 is connected to the syringe 68.
[0058] As shown in FIG. 21, the inner peripheral surface of the guide tube portion 118 is provided with a tip support guide 138 of the guide mechanism 28, which will be described later.
[0059] As shown in FIG. 5 , the guide mechanism 28 is interposed between the housing 16 and the syringe unit 20A. The guide mechanism 28 has a guide rib extending along the axial direction of the housing 16 and a guide groove extending along the axial direction and engaging with the guide rib. Specifically, the guide mechanism 28 includes a first guide portion 126 provided on the outer peripheral surface of the syringe holder 70A and extending along the axial direction, and a second guide portion 128 formed on the inner peripheral surfaces of the housing 16 and the needle hub 24A held by the housing 16, extending along the axial direction, and engaging with the first guide portion 126. A plurality of first guide portions 126 are provided along the circumferential direction of the syringe holder 70A. A plurality of second guide portions 128 are provided along the circumferential direction of the housing 16 and the needle hub 24A.
[0060] As shown in Figure 11, the first guide portion 126 is provided in multiple locations along the circumferential direction of the syringe holder 70A, and has a tip slide guide 130 (see Figure 22) provided at the tip end of the syringe holder 70A, and a base end slide guide 132 (see Figure 23) provided at the base end of the syringe holder 70A.
[0061] 22 , the tip slide guide 130 is a plurality of first guide ribs 134 that protrude radially outward from the outer peripheral surface of the holder tip tubular portion 100 of the syringe holder 70A. Four first guide ribs 134 are provided at equal intervals along the circumferential direction of the holder tip tubular portion 100. When viewed in the axial direction of the syringe holder 70A, the cross-sectional shape of each first guide rib 134 is a triangle that tapers radially outward.
[0062] 23 , the proximal slide guide 132 is a plurality of second guide ribs 136 that protrude radially outward from the outer circumferential surface of the curved portion 104 of the syringe holder 70A. Three second guide ribs 136 are provided on each of the pair of curved portions 104, spaced apart from each other along the circumferential direction. There are a total of six second guide ribs 136. When viewed in the axial direction of the syringe holder 70A, the cross-sectional shape of each second guide rib 136 is substantially rectangular.
[0063] As shown in FIG. 22, the second guide portion 128 has a tip support guide 138 that is provided on the guide tube portion 118 of the needle hub 24A and supports the tip slide guide 130.
[0064] The tip support guide 138 is a plurality of first guide grooves 142 recessed radially outward from the inner circumferential surface of the guide tube portion 118. Four first guide grooves 142 are provided at equal intervals along the circumferential direction of the guide tube portion 118. The first guide ribs 134 can be inserted into the first guide grooves 142. That is, there are the same number of first guide grooves 142 and first guide ribs 134. When viewed in the axial direction of the needle hub 24A, the cross-sectional shape of the first guide grooves 142 is triangular and tapers radially outward.
[0065] When the first guide rib 134 is inserted into the first guide groove 142, there is a slight clearance between the first guide groove 142 and the first guide rib 134. The clearance between the first guide rib 134 and the first guide groove 142 is the smallest clearance between the syringe holder 70A and the needle hub 24A (see FIG. 22).
[0066] When the syringe unit 20A including the syringe holder 70A moves toward the tip along the housing 16, the first guide rib 134 is guided along the first guide groove 142, thereby guiding the tip of the syringe unit 20A toward the tip.
[0067] 23 , the second guide portion 128 has a base end support guide 140 that is provided in the housing 16 and supports the base end slide guide 132. The base end support guide 140 is a plurality of second guide grooves 144 that are recessed radially outward from the inner circumferential surface of the cylindrical portion of the housing 16. Six second guide grooves 144 are provided spaced apart from one another along the circumferential direction of the cylindrical body 36. The second guide ribs 136 can be inserted into the second guide grooves 144. That is, there are the same number of second guide grooves 144 and second guide ribs 136. When viewed in the axial direction of the housing 16, the cross-sectional shape of the second guide grooves 144 is approximately rectangular.
[0068] When syringe unit 20A including syringe holder 70A moves toward the distal end, second guide rib 136 is guided along second guide groove 144, thereby guiding the base end of syringe unit 20A toward the distal end. In other words, first and second guide portions 126, 128 improve the linearity of syringe unit 20A when it moves toward the distal end.
[0069] 6 and 24, the drive unit 34 includes a plunger 30 that is inserted into the syringe 68 and can press the gasket 76 in the distal direction (the direction of arrow B), an injection spring (biasing member) 146 that biases the plunger 30 in the distal direction, and a locking mechanism 32 that prevents the plunger 30 from moving in the distal direction in an initial state before the user performs a puncture operation. The drive unit 34 is disposed near the base end of the housing 16 in the medical solution administration device 12A shown in FIG.
[0070] 6, the plunger 30 is a cylindrical body that is long in the axial direction (the direction of arrows A and B), and is disposed axially movably inside the housing 16. The plunger 30 is formed with a substantially constant diameter along the axial direction, and is disposed distally (in the direction of arrow B) relative to the lid portion 48 of the end cap 38, with its distal end inserted into the barrel 74 of the syringe 68. In the initial state shown in FIG. 6, the distal end of the plunger 30 is disposed a predetermined distance away from the gasket 76 in the proximal direction (in the direction of arrow A).
[0071] The shaft portion 54 of the end cap 38 and the injection spring 146 are inserted into the plunger 30. As shown in Figures 7 and 8, the plunger 30 has a pair of lock holes 150 on its outer circumferential surface. The lock holes 150 are formed near the base end of the plunger 30 and penetrate radially inward from the outer circumferential surface of the plunger 30. The pair of lock holes 150 are disposed symmetrically with respect to the axial center of the plunger 30, and lock claws 172 of a lock body 156 in a lock mechanism 32 (described later) engage with the lock holes 150 from the radially outer side.
[0072] The injection spring 146 is a coil spring and is longer in the axial direction than the shaft portion 54. As shown in Fig. 6, the injection spring 146 is interposed between the inner surface of the tip of the plunger 30 and the end face of the lid portion 48 of the end cap 38, and the spring force of the injection spring 146 urges the plunger 30 toward the tip (in the direction of arrow B).
[0073] Locking mechanism 32 prevents plunger 30 from moving distally (in the direction of arrow B) in the initial state before the user performs the puncturing operation. As shown in Figures 6 and 25, locking mechanism 32 includes a locking member 152 housed inside housing 16 so as to be displaceable in the axial direction, a locking sleeve spring (elastic member) 154 that biases locking member 152 distally, and a locking body 156 that engages with plunger 30 in the initial state to prevent plunger 30 from moving distally.
[0074] The locking member 152 is formed in a cylindrical shape that surrounds the plunger 30. In the initial state shown in Figure 8, the locking member 152 is positioned on the outer periphery facing the locking hole 150 of the plunger 30, and in the puncture state, it is pushed up by the needle cover 18A, moves toward the base end, and is positioned on the outer periphery of the retaining cylindrical portion 52 of the end cap 38 (see Figure 29).
[0075] 6 and 8, the locking member 152 includes a cylindrical portion 158 and a flange portion 160 provided at the tip of the cylindrical portion 158. The base end of the cylindrical portion 158 has an inclined portion 162 that protrudes radially inward from the inner circumferential surface of the cylindrical portion 158. The tip surface of the inclined portion 162 inclines from the inner circumferential surface of the cylindrical portion 158 toward the base end (direction of arrow A).
[0076] Flange portion 160 extends radially outward from the base end of cylindrical portion 158. When needle cover 18A moves relative to housing 16 in the base end direction during puncturing as shown in Figures 28 and 29, the base end of extension portion 62 of needle cover 18A abuts against flange portion 160, and locking member 152 is pushed up in the base end direction (direction of arrow A).
[0077] 6, the outer peripheral surface of the locking member 152 has a pair of hook portions 164 extending from the flange portion 160 toward the base end. The hook portions 164 are formed in locking holes 166 that open into the outer peripheral surface of the locking member 152, and have a cantilever structure in which the tips of the hook portions 164 are fixed to the locking holes 166. The base ends of the hook portions 164 are disposed inside the locking holes 166 and are engageable with body protrusions 177 of the lock body 156 that are inserted into the locking holes 166.
[0078] The lock sleeve spring 154 is a coil spring disposed on the outer periphery of the lock member 152, and is interposed between the lid portion 48 of the end cap 38 and the flange portion 160 of the lock member 152. The resilient force of the lock sleeve spring 154 biases the lock member 152 toward the tip (direction of arrow B).
[0079] 5 to 8, lock body 156 is disposed inside end cap 38 within housing 16. Lock body 156 is disposed near the base end of plunger 30 and includes body holes 168 with which engaging projections 56 of end cap 38 engage, a pair of engaging arms 170 that are elastically deformable in the radial direction, a pair of locking claws 172 provided at the tips of engaging arms 170, and a pair of body protrusions 177 that protrude radially outward from the outer circumferential surface.
[0080] The body hole 168 opens on the outer peripheral surface of the lock body 156 and penetrates radially inward. The retaining cylindrical portion 52 of the end cap 38 is disposed inside the lock body 156, and the engaging projection 56 of the end cap 38 engages with the body hole 168 (see FIGS. 6 and 8). This secures the lock body 156 to the end cap 38.
[0081] As shown in Figure 8, the pair of engagement arms 170 are arranged in the distal direction of the body hole 168 (in the direction of arrow B). The base ends of the engagement arms 170 are fixed ends, and the distal ends of the engagement arms 170 are free ends that are not fixed. The engagement arms 170 are elastically deformable with the base ends as fulcrums. The pair of engagement arms 170 are arranged symmetrically with respect to the axial center of the lock body 156.
[0082] The locking claw 172 protrudes radially inward and radially outward from the tip of the engagement arm 170. The locking claw 172 includes a first claw portion 174 that protrudes radially inward from the tip of the engagement arm 170, and a second claw portion 176 that protrudes radially outward from the tip.
[0083] The base end of the first claw 174 has an inclined surface that slopes radially inward toward the tip. In the initial state shown in Figure 8 before the user performs the puncture operation, the inclined surface of the first claw 174 engages with the lock hole 150 of the plunger 30. At this time, because the lock member 152 is disposed on the outer periphery of the engagement arm 170, the engagement arm 170 is prevented from deforming radially outward, and the engagement state between the lock claw 172 and the lock hole 150 is maintained.
[0084] That is, in the locking mechanism 32, the first claw portion 174 of the locking claw 172 engages with the locking hole 150 of the plunger 30, thereby preventing the plunger 30 from moving toward the tip (in the direction of arrow B).
[0085] 28 and 29 is performed, when the locking member 152 moves relative to the housing 16 in the proximal direction (direction of arrow A) together with the needle cover 18A, the locking member 152 is positioned proximally further than the engaging arm 170. As a result, the engaging arm 170 becomes deformable radially outward, and the locking claw 172 of the engaging arm 170 disengages from the locking hole 150 of the plunger 30, thereby releasing the engagement between the engaging arm 170 and the plunger 30. This releases the state in which the movement of the plunger 30 is prevented by the locking claw 172 of the locking mechanism 32.
[0086] The base end of the second claw portion 176 has an inclined surface that slopes radially outward toward the distal end, and when the locking member 152 moves distally due to the elastic force of the locking sleeve spring 154, the locking member 152 comes into contact with the engaging arm 170, causing the engaging arm 170 to elastically deform radially inward. This allows the locking member 152 to move distally over the locking claw 172 of the engaging arm 170. In other words, the locking mechanism 32 enters an unlocked state in which the plunger 30 can move distally as the needle cover 18A moves proximally. The locking mechanism 32 enters the unlocked state when the locking member 152 moves proximally and reaches the unlocked position.
[0087] A pair of body protrusions 177 are formed on the outer peripheral surface of the tip of the lock body 156 and protrude radially outward from the outer peripheral surface. The body protrusions 177 are arranged symmetrically about the axial center of the lock body 156. As shown in Figure 37, when the puncture operation is completed and the needle cover 18A and lock member 152 move toward the tip, the body protrusions 177 are inserted into the engagement holes 166 of the lock member 152 and engage with the base ends of the hook portions 164. This prevents the lock member 152 from moving in the axial direction by the body protrusions 177.
[0088] The packaging container 14 shown in Fig. 1 accommodates a medicinal liquid administration device 12A in a sealed state. As shown in Fig. 2, the packaging container 14 includes a container body 178 in which the medicinal liquid administration device 12A is accommodated, a sealing film 180, and an actuation prevention protrusion 182 that can prevent actuation of the drive unit 34 (see Fig. 5, etc.) when the medicinal liquid administration device 12A is accommodated. The container body 178 is formed in a substantially rectangular shape in a plan view. Hereinafter, the long dimension direction of the container body 178 will be referred to as the longitudinal direction, and the short dimension direction of the container body 178 that is perpendicular to the longitudinal direction will be referred to as the width direction.
[0089] Container body 178 has a storage recess 184 in which medicinal solution administration device 12A is stored, and an opening edge 188 surrounding an opening 186 for removing medicinal solution administration device 12A. Container body 178 is formed from a relatively hard resin material. One longitudinal end of container body 178 has a bulge 190 that bulges out in a semicircular shape in the longitudinal direction. Opening edge 188 is formed in a rectangular shape along opening 186 of storage recess 184, and has a flange-like shape that extends outward from opening 186.
[0090] The accommodating recess 184 is recessed downward from an opening edge 188 formed at the upper end of the container body 178, and is formed so as to be able to accommodate the medicinal liquid administration device 12A. The accommodating recess 184 has a bottom 184a formed in the opposite direction to the opening 186. The bottom 184a is flat along the longitudinal and width directions of the container body 178, and the medicinal liquid administration device 12A is placed on a plurality of mounting portions 192 protruding from the bottom 184a.
[0091] The mounting portions 192 are formed in a shape corresponding to the external shape of the medicinal solution administration device 12A, and are arranged spaced apart from each other along the longitudinal direction of the container body 178. The mounting portions 192 are formed so as to connect the side walls of the container body 178 in the width direction.
[0092] When the chemical solution administration device 12A is accommodated in the accommodation recess 184, the chemical solution administration device 12A is held substantially horizontally by the plurality of mounting portions 192, and the base end side of the chemical solution administration device 12A is accommodated at one longitudinal end having the bulge 190, and the tip side of the chemical solution administration device 12A is accommodated at the other longitudinal end. As shown in Figure 26, when the chemical solution administration device 12A is accommodated in the packaging container 14, the hole 42 of the housing 16 is located further proximally (in the direction of arrow A) than the flange 160 of the locking member 152 of the drive unit 34.
[0093] The sealing film 180 is made of a resin material such as polyethylene resin. The sealing film 180 is a flexible, thin sheet. In a plan view of the medicinal solution administration system 10A, the sealing film 180 has a rectangular shape with approximately the same dimensions as the container body 178.
[0094] The sealing film 180 is placed so as to cover the opening edge 188 of the container body 178, and the outer edge of the sealing film 180 is overlapped with the opening edge 188 and heated. This bonds (fuses) the outer edge of the sealing film 180 to the opening edge 188 of the container body 178. The container body 178 and the sealing film 180 accommodate the medicinal solution administration device 12A in a sealed state inside the container body 178 (accommodation recess 184) (see FIGS. 1 and 26 ).
[0095] A grip portion 194 extending in the longitudinal direction is provided at one longitudinal end of the sealing film 180. When the sealing film 180 is fused to the container body 178, the grip portion 194 protrudes outward (in the longitudinal direction) from the container body 178.
[0096] When a user removes the drug solution administration device 12A from the packaging container 14, the user grasps the handle 194 and pulls the sealing film 180 upward relative to the container body 178, peeling the sealing film 180 off from the opening edge 188 of the container body 178 to open the container body 178.
[0097] 2, the activation preventing protrusion 182 is provided integrally with a mounting portion 192 located at one end closest to the longitudinal end. The activation preventing protrusion 182 is provided on the bottom 184a of the accommodation recess 184 together with the mounting portion 192, and protrudes from the bottom 184a toward the opening 186, and protrudes further toward the opening 186 than the mounting portion 192. A pair of activation preventing protrusions 182 are arranged spaced apart in the width direction of the container body 178.
[0098] As shown in Figure 27, when the medicinal liquid administration device 12A is accommodated in the accommodation recess 184 and placed on the mounting portion 192, the end of the activation prevention protrusion 182 is inserted into the interior of the housing 16 through the hole portion 42 of the housing 16.
[0099] 26 , when the medical solution administration device 12A is contained in the packaging container 14, the medical solution administration device 12A is in an initial state before a puncture operation is performed. In the initial state of the medical solution administration device 12A, the activation preventing protrusion 182 is positioned further proximally (in the direction of arrow A) than the flange 160 of the locking member 152 of the drive unit 34. In other words, the activation preventing protrusion 182 is positioned between an initial position in which the locking member 152 is positioned distally, and an unlocked position in which the needle cover 18A has moved proximally relative to the housing 16 and the locking member 152 has moved proximally.
[0100] When the chemical solution administration device 12A is housed in the packaging container 14, the activation preventing protrusion 182 is inserted into the housing 16 through the hole 42, thereby preventing the locking member 152 from moving to the unlocked position. In other words, when the chemical solution administration device 12A is housed in the packaging container 14, the activation preventing protrusion 182 restricts the movement of the locking member 152 toward the proximal end, thereby preventing the activation of the drive unit 34. When the chemical solution administration device 12A is removed from the packaging container 14, the activation preventing protrusion 182 is removed from the housing 16, thereby releasing the activation prevention of the drive unit 34.
[0101] Next, a case where the medicinal liquid administration device 12A is removed from the packaging container 14 and a puncturing operation is performed in the medicinal liquid administration system 10A will be described.
[0102] As described above, when the medical solution administration device 12A is housed in the packaging container 14, the activation preventing protrusion 182 is inserted into the housing 16 through the hole 42 and is positioned in the proximal direction relative to the flange 160 of the locking member 152. Therefore, movement of the locking member 152 in the proximal direction is restricted.
[0103] Therefore, when an unopened drug solution administration system 10A is accidentally dropped and an external force is applied, the activation prevention protrusion 182 prevents the locking member 152 from moving to the unlocked position, and prevents the drive unit 34 from being activated as the locking member 152 moves toward the base end.
[0104] In the drug solution administration system 10A shown in FIG. 1, the user grasps the grip portion 194 of the sealing film 180 and peels the sealing film 180 upward from the container body 178 to open the container body 178.
[0105] The user inserts his or her finger into the bulge 190 through the opening 186 of the opened container body 178 and removes the liquid medicine administration device 12A from the base end side through the opening 186 to the outside of the packaging container 14 (see FIG. 2 ). At this time, the activation preventing protrusion 182 is removed from the hole 42 of the housing 16, thereby releasing the activation prevention of the drive unit 34 by the activation preventing protrusion 182. In other words, the removal of the activation preventing protrusion 182 causes the drive unit 34 to transition from an activation prevented state to an activation released state. Because the activation preventing protrusion 182 is provided on the bottom 184 a of the storage recess 184 and protrudes toward the opening 186, the activation preventing protrusion 182 is easily and reliably removed from inside the housing 16 by moving the liquid medicine administration device 12A toward the opening 186 and removing it to the outside.
[0106] The medicinal liquid administration device 12A removed from the packaging container 14 is in an initial state, which is the state before puncturing, as shown in Figures 5 and 7. In the initial state of the medicinal liquid administration device 12A, the locking claw 172 of the engagement arm 170 of the lock body 156 is inserted from the radially outer side into the locking hole 150 of the plunger 30, and the engagement arm 170 is prevented from tilting radially outward (elastic deformation) by the locking member 152, which is biased distally by the locking sleeve spring 154. In other words, the engagement arm 170 cannot elastically deform radially outward. Therefore, the plunger 30 is in a locked state in which distal movement is prevented by the locking mechanism 32 of the drive unit 34.
[0107] The user grasps housing 16 of drug solution administration device 12A and presses the tip of needle cover 18A protruding from the tip of housing 16 against the desired puncture site on skin S at a substantially right angle. By continuously pressing housing 16 further toward skin S (tip side, direction of arrow B), needle cover 18A is pressed against skin S, and needle cover 18A moves relative to housing 16 in the proximal direction (direction of arrow A) against the elastic force of cover spring 122, as shown in Figures 28 and 30 .
[0108] 28 and 30, as the needle cover 18A moves relative to the proximal end, the first needle portion 112 of the double-ended needle 22 protrudes from the distal opening 64 of the needle cover 18A toward the distal end (in the direction of arrow B). As a result, the first needle portion 112 of the double-ended needle 22 punctures the skin S and enters a puncture state in which it is inserted to a predetermined depth.
[0109] 28 and 29 , as needle cover 18A moves proximally (in the direction of arrow A), the proximal end of extension 62 of needle cover 18A abuts against flange 160 of locking member 152 and pushes it up proximally (in the direction of arrow A). Locking member 152 moves proximally while compressing lock sleeve spring 154 with needle cover 18A. When locking member 152 reaches the unlocked position where locking member 152 is positioned proximally further than engaging arm 170 having locking claw 172, engaging arm 170 can elastically deform outward.
[0110] The spring force of the injection spring 146 urges the plunger 30 of the drive unit 34 toward the tip (direction of arrow B), tilting the engagement arm 170 along the lock hole 150 and moving the lock claw 172 outward, causing the lock claw 172 to disengage from the lock hole 150 (see Figure 29).
[0111] This releases the plunger 30 from the locked state by the locking claw 172 that constitutes the locking mechanism 32, and the plunger 30 begins to move toward the tip (in the direction of arrow B) due to the elastic force of the injection spring 146. In other words, the needle cover 18A functions as an activation switch for activating the drive unit 34 (plunger 30), which is prevented from activation in the initial state before the user performs the puncture operation.
[0112] When plunger 30 begins to move distally, the distal end of plunger 30 abuts against the base end of gasket 76. Then, plunger 30 pushes gasket 76 distally, and plunger 30 and gasket 76 move together. At this time, chamber 72, which is located distally of gasket 76, is filled with liquid medicine M, and the distal hole (nozzle hole 84) of barrel 74 is blocked by lid 94, so liquid medicine M is not discharged from barrel 74.
[0113] Therefore, the medicinal solution M filled in the barrel 74 prevents the gasket 76 from moving in the distal direction, and the plunger 30 moves in the distal direction, pushing the syringe unit 20A including the syringe 68 in the distal direction via the gasket 76. This causes the second engaging portion 46b of the syringe holder 70A to disengage from the second engaging hole 44b of the housing 16, and the syringe holder 70A is released from the housing 16 (see FIG. 31 ).
[0114] Syringe unit 20A pushed by plunger 30 starts to move toward the distal end along housing 16. At this time, second guide rib 136 of syringe holder 70A moves toward the distal end along second guide groove 144, thereby guiding syringe unit 20A including syringe holder 70A toward the distal end (see FIG. 23 ).
[0115] As plunger 30 moves distally, syringe unit 20A moves distally, and holder tip tube portion 100 of syringe holder 70A is inserted into guide tube portion 118 of needle unit 26A via hub body 116. As shown in Fig. 22, multiple first guide ribs 134 provided on holder tip tube portion 100 are inserted into first guide grooves 142 of guide tube portion 118, thereby guiding the tip of syringe unit 20A distally along needle hub 24A.
[0116] That is, by providing a first guide portion 126 on the outer peripheral surface of the syringe holder 70A, and providing a second guide portion 128 on the inner peripheral surfaces of the needle hub 24A and the housing 16, and engaging the first guide portion 126 with the second guide portion 128, when the syringe unit 20A moves toward the tip along the housing 16, tilting of the syringe unit 20A relative to the housing 16 is effectively prevented, and the straightness of the syringe unit 20A toward the tip can be improved.
[0117] As syringe unit 20A moves further toward the distal end, the distal end of syringe unit 20A approaches second needle portion 114 of double-ended needle 22, and second needle portion 114 begins to pierce lid body 94. As shown in Figures 31 and 32, the base end of second needle portion 114 penetrates lid body 94 and is inserted into barrel 74 through nozzle hole 84. This connects chamber 72 of syringe 68 and double-ended needle 22 via second needle portion 114, and communicates chamber 72 with the user's subcutaneous tissue via lumens 112a, 114a of double-ended needle 22.
[0118] After the second needle portion 114 of the double-ended needle 22 and the tip of the syringe 68 are connected, the syringe unit 20A moves further toward the tip, causing the tip of the cap 78 held by the holder tip tube portion 100 of the syringe holder 70A to abut against the support portion 124 of the needle hub 24A (see FIGS. 31 and 32 ). This prevents the syringe unit 20A from moving toward the tip and stops the syringe unit 20A at a predetermined position, and the second needle portion 114 is inserted further deeply into the barrel 74, thereby completing the connection between the double-ended needle 22 and the syringe 68.
[0119] After the distal movement of syringe unit 20A stops, gasket 76 is continuously pushed distally by plunger 30, and the sealed state of chamber 72 is released by connection with double-ended needle 22, so that gasket 76, pushed by the tip of plunger 30, becomes movable distally within chamber 72. Pushed by plunger 30, gasket 76 moves distally along barrel 74, causing gasket 76 to push out medicinal solution M from chamber 72 distally. This causes medicinal solution M to be expelled from lumen 114a of second needle portion 114 of double-ended needle 22 through lumen 112a of first needle portion 112, commencing subcutaneous administration of medicinal solution M to the user.
[0120] As shown in FIG. 33, when the gasket 76 pushed by the plunger 30 reaches the tip of the chamber 72, administration of all of the medicinal liquid M filled in the chamber 72 is completed.
[0121] For example, a plunger 30a according to a modified example shown in Fig. 34 may be employed. The outer peripheral surface of the plunger 30 has a pair of protrusions 196 that protrude radially outward. The protrusions 196 are disposed near the base end of the plunger 30a and protrude in a direction perpendicular to the axial direction of the plunger 30a. The pair of protrusions 196 are disposed symmetrically with respect to the axial center of the plunger 30a.
[0122] When the second needle portion 114 of the double-ended needle 22 is connected to the tip of the syringe 68 and the plunger 30a pushes the gasket 76 toward the tip to administer the medicinal liquid M, the movement of the gasket 76 causes the medicinal liquid M in the medicine chamber 72 to begin to be administered through the double-ended needle 22, and the plunger 30a moves and the convex portion 196 comes into contact with the flange 80 of the syringe 68, stopping the movement of the plunger 30a toward the tip.
[0123] 34 , by causing protrusion 196 to stop the movement of plunger 30a toward the tip before gasket 76 reaches the tip of chamber 72, it is possible to administer only a portion of the medicinal liquid M filled in chamber 72. Therefore, it is possible to administer only a predetermined amount of medicinal liquid M in chamber 72.
[0124] After administration of medicinal solution M shown in Figure 33 is completed, the user releases the pressure on the medicinal solution administration device 12A against the skin S, which causes the elastic force of the cover spring 122 to urge the needle cover 18A toward the distal end (in the direction of arrow B). As shown in Figure 35, the distal end of the needle cover 18A protrudes from the distal end of the housing 16 and moves to a position where it is more distal than the first needle portion 112 of the double-ended needle 22. This causes the first needle portion 112 of the double-ended needle 22 to be completely covered by the needle cover 18A. The first engagement portion 46a of the needle cover 18A engages with the first engagement hole 44a of the housing 16.
[0125] As needle cover 18A moves distally, the biasing force of locking member 152 by needle cover 18A toward the proximal end is released, and locking member 152 moves distally (in the direction of arrow B) due to the resilient force of locking sleeve spring 154. As shown in Figure 36A, as locking member 152 moves distally, inclined portion 162 abuts against second claw portion 176 of locking claw 172. At this time, because plunger 30 has moved distally, plunger 30 is not positioned inside locking claw 172.
[0126] 36B, when the locking member 152 moves further in the distal direction, the locking claws 172 are pushed inward by the inclined portions 162, the engaging arms 170 are elastically deformed inward, and the inclined portions 162 move over the locking claws 172 in the distal direction. In other words, the locking member 152 becomes movable in the distal direction further than the locking body 156.
[0127] 35 and 37, when the locking member 152 moves distally from the locking body 156, the body protrusion 177 of the locking body 156 is inserted into the locking hole 166 of the locking member 152, and the body protrusion 177 is held by the base end of the hook portion 164 and the locking hole 166. As a result, the locking member 152 is held by the locking body 156 and prevented from moving in the axial direction.
[0128] 38, the extension 62 of the needle cover 18A abuts against the tip (flange 160) of the locking member 152, thereby preventing the needle cover 18A from moving proximally (in the direction of arrow A). Because the needle cover 18A is prevented from moving proximally after puncture, even if a force acts on the needle cover 18A in the proximal direction, the first needle portion 112 of the double-ended needle 22 is not exposed to the outside by the needle cover 18A, ensuring safety.
[0129] As described above, in drug solution administration device 12A of drug solution administration system 10A, when the tip of needle cover 18A is pressed against the user's skin S and needle cover 18A moves in the proximal direction, the movement prevention state of plunger 30 by locking mechanism 32 is released, and plunger 30 moves in the distal direction due to the elastic force of injection spring 146, pushing gasket 76 of syringe 68 in the distal direction. As a result, syringe 68 moves in the distal direction together with plunger 30, second needle portion 114 of double-ended needle 22 is punctured into the tip of syringe 68, and gasket 76 moves in the distal direction along chamber 72 of barrel 74, whereby drug solution M is administered from chamber 72 through double-ended needle 22 that has been inserted subcutaneously into the user's skin.
[0130] As a result, in conjunction with the user's puncture operation, it becomes possible to automatically and continuously connect the double-ended needle 22 to the syringe 68 and administer the medicinal solution M subcutaneously from the double-ended needle 22. Therefore, the double-ended needle 22 and the syringe 68 can be connected simply and reliably without the user having to perform the operation of connecting the double-ended needle 22 and the syringe 68.
[0131] When syringe unit 20A moves toward the distal end, the distal end of holder distal end tube portion 100, which is the distal end of syringe holder 70A, abuts against support portion 124 of guide tube portion 118 of needle hub 24A, thereby reliably stopping the distal movement of syringe unit 20A. Therefore, after syringe 68 is connected to second needle portion 114 of double-ended needle 22, plunger 30 pushes and moves gasket 76 toward the distal end relative to barrel 74 of syringe 68, and administration of medicinal solution M can be initiated by gasket 76.
[0132] By placing a syringe holder 70A on the outer periphery of the syringe 68 and holding the syringe 68 by the syringe holder 70A, when the syringe unit 20A moves toward the tip, the syringe holder 70A is guided toward the tip along the housing 16, thereby making it possible to move the syringe 68 stably toward the tip.
[0133] In the initial state before the puncture operation is performed, the second engagement portion 46b of the syringe holder 70A engages with the second engagement hole 44b of the housing 16, and the syringe holder 70A is axially locked to the housing 16. Therefore, in the initial state in which the movement of the plunger 30 is prevented by the locking mechanism 32, the syringe 68 can be held in a predetermined position relative to the housing 16.
[0134] The locking mechanism 32 comprises a locking member 152 displaceably provided inside the housing 16, a locking sleeve spring 154 that urges the locking member 152 in the distal direction, and a locking body 156 that engages with the locking hole 150 of the plunger 30 in the initial state to prevent the plunger 30 from moving in the distal direction. By urging the locking member 152 in the distal direction with the locking sleeve spring 154 and maintaining the engagement of the plunger 30 with the locking claw 172 of the locking body 156, the plunger 30 can be prevented from moving in the distal direction.
[0135] In the initial state before the puncture operation is performed, the engagement arm 170 of the lock body 156 engages with the lock hole 150 of the plunger 30 from the radially outer side, and the lock member 152 prevents the engagement arm 170 from tilting radially outward. Therefore, in the initial state, the plunger 30 can be reliably prevented from moving toward the distal end, and by moving the lock member 152 toward the proximal end, the engagement of the engagement arm 170 with the plunger 30 can be released, allowing the plunger 30 to move toward the distal end.
[0136] When the locking member 152 moves distally due to the elastic force of the locking sleeve spring 154, the locking member 152 comes into contact with the engaging arm 170 of the lock body 156, thereby elastically deforming the engaging arm 170 radially inward, and allowing the locking member 152 to move distally. Therefore, the distal movement of the locking member 152 pushes the needle cover 18A distally, thereby moving the needle cover 18A and covering the first needle portion 112 of the double-ended needle 22 with the needle cover 18A.
[0137] Next, the chemical liquid administration system 10B will be described with reference to Figures 39 to 44. Note that the same components as those in the chemical liquid administration system 10A are given the same reference numerals, and detailed description thereof will be omitted.
[0138] A chemical solution administration system 10B shown in FIG. 39 includes a chemical solution administration device 12B and a packaging container 14 having a sterilized internal space 14a in which the chemical solution administration device 12B is housed.
[0139] 39 and 40 , a drug solution administration device 12B has a needle unit 26B, which includes a needle hub 24B, a first bacteria-shielding cover 200 attached to a first needle portion 112 of a double-ended needle 22 supported by the needle hub 24B, and a second bacteria-shielding cover 202 attached to a second needle portion 114 of the double-ended needle 22. In the double-ended needle 22, a bacteria-shielding cover may be attached only to the first needle portion 112 that is inserted into the skin S of the user.
[0140] 40 , the needle hub 24B includes a first annular protrusion 204 that protrudes distally (in the direction of arrow B) from the center of the support portion 124, and a second annular protrusion 206 that protrudes proximally (in the direction of arrow A) from the center of the support portion 124. The first annular protrusion 204 supports the first needle portion 112, and the second annular protrusion 206 supports the second needle portion 114.
[0141] The first and second bacteria-shielding covers 200, 202 are each formed in a cylindrical shape from an elastic material such as silicone rubber, butyl rubber, elastomer, or the like, and are axially contractible. With the first and second bacteria-shielding covers 200, 202 attached to the double-ended needle 22, the double-ended needle 22 together with the needle hub 24B is irradiated with an electron beam or radiation, and the double-ended needle 22 is sterilized by either electron beam sterilization or radiation sterilization. The first and second bacteria-shielding covers 200, 202 are formed from a material that is permeable to electron beams or radiation.
[0142] The first bacteria-shielding cover 200 comprises a first cover distal end portion 208 that covers the distal end portion of the first needle portion 112 in the initial state before puncture is performed as shown in Figure 40, and a first cover proximal end portion 210 that is connected to the support portion 124 of the needle hub 24B. The first cover distal end portion 208 has a seat 208a that is perpendicular to the extension direction of the first bacteria-shielding cover 200. The first cover proximal end portion 210 is open and engages with the outer periphery of the first annular protrusion 204 of the needle hub 24B, and is connected to and held by the first annular protrusion 204.
[0143] The base 208a is formed in a disk shape, and when the first bacteria-shielding cover 200 is folded in the axial direction during puncture with the first needle part 112 shown in Figure 41, the base 208a is accommodated and held in a receiving part 218 formed on the inner surface of the tip of the main body part 58 of the needle cover 18B. The receiving part 218 is formed in the center of the inner surface of the tip of the needle cover 18B and is cup-shaped and annularly erected toward the base end. A tip opening 64 is open in the center of the receiving part 218.
[0144] The second antibacterial cover 202 comprises a second cover tip portion 212 connected to the support portion 124 of the needle hub 24B, and a second cover base portion 214 that covers the base portion (needle tip) of the second needle portion 114 in the initial state before puncture is performed as shown in Figure 40.
[0145] The second cover distal end portion 212 is open and engages with the outer periphery of the second annular protrusion 206 of the needle hub 24B, and is connected to and held by the second annular protrusion 206. In the initial state, the second cover proximal end portion 214 is inserted into the insertion hole 92 of the cap 78.
[0146] Next, a case where a sterilization process is performed during manufacturing of the chemical solution administration system 10B including the chemical solution administration device 12B described above will be described with reference to FIGS. 43A to 44.
[0147] First, before assembling the drug solution administration device 12B, as shown in FIG. 43A, the needle unit 26B including the double-ended needle 22 is subjected to electron beam sterilization or radiation sterilization, which is a first sterilization method (first sterilization step).
[0148] 43A, a needle unit 26B including a double-ended needle 22 with a first bacteria-shielding cover 200 attached to the first needle portion 112 and a second bacteria-shielding cover 202 attached to the second needle portion 114 is placed into a first sterilization chamber 222 of a first sterilization device 220. In the first sterilization chamber 222, electron beams or radioactive rays are irradiated from an irradiation source 224 onto the needle unit 26B for a predetermined period of time.
[0149] The electron beam or radiation penetrates the first and second bacteria-shielding covers 200, 202, thereby sterilizing the first and second needle portions 112, 114 with electron beams or radiation. This ensures the sterility of the double-ended needle 22 covered by the first and second bacteria-shielding covers 200, 202.
[0150] Next, before assembling the drug solution administration device 12B, the syringe 68 is subjected to autoclave sterilization (high-pressure steam sterilization), which is a second sterilization method (second sterilization step).
[0151] 43B, the syringe 68, in which the chamber 72 of the barrel 74 is filled with the medicinal solution M and the medicinal solution M is sealed, is placed into the second sterilization chamber 228 of the second sterilization device 226. High-pressure steam is supplied into the second sterilization chamber 228 through the piping 230.
[0152] The syringe 68 is heated to a predetermined temperature in the second sterilization chamber 228 by high-pressure steam, and the syringe 68 is sterilized.
[0153] Finally, after assembling the drug solution administration device 12B, including the needle unit 26B sterilized by the first sterilization method and the syringe 68 sterilized by the second sterilization method, the drug solution administration device 12B is accommodated in the accommodation recess 184 of the packaging container 14 as shown in Figure 44, and the internal space 14a of the packaging container 14 is sterilized by the third sterilization method (third sterilization step).
[0154] 44 is accommodated in the accommodation recess 184 of the packaging container 14, sterilized water W is dripped from the supply nozzle 234 of the dripping device 232 into the accommodation recess 184 (internal space 14a) through the opening 186 of the container body 178. The sterilized water W is hydrogen peroxide solution. After a predetermined amount of sterilized water W is dripped from the supply nozzle 234 into the accommodation recess 184, the container body 178 is sealed by fusing the sealing film 180 to the opening edge 188 of the container body 178.
[0155] By leaving the drug solution administration system 10B in an environment above room temperature, the sterilized water W gradually vaporizes within the packaging container 14, filling the internal space 14a of the packaging container 14 as sterilized gas. The sterilized gas filling the internal space 14a can suitably sterilize the interior and exterior surfaces of the drug solution administration device 12B. This sterilizes the area between the lid 94 provided at the tip of the drug chamber 72 of the syringe 68 and the second needle portion 114 of the double-ended needle 22 that is inserted into the lid 94, ensuring sterility between the two.
[0156] The needle body of the drug solution administration device 12B to which the bacteria-shielding cover is attached is not limited to the double-ended needle 22 having the first and second needle portions 112, 114. The needle body may be a single-ended needle that is connected to the tip of the syringe 68 in advance.
[0157] Next, the operation of the sterilized chemical liquid administration device 12B will be described. Note that detailed explanations of the same operations as those of the chemical liquid administration device 12A will be omitted.
[0158] From the initial state before the puncture operation shown in Figure 40, when the user presses the tip of the needle cover 18B against the skin S and the needle cover 18B moves relative to the housing 16 in the proximal direction, as the needle cover 18B moves in the proximal direction, the base 208a of the first antibacterial cover 200 is inserted into the receiving portion 218 of the needle cover 18B, and then the first cover tip portion 208 is pushed up in the proximal direction (direction of arrow A) together with the needle cover 18B via the base 208a.
[0159] 41 , as the first cover distal portion 208 including the base 208a moves in the proximal direction, the needle tip of the first needle portion 112 punctures the base 208a and penetrates the base 208a to protrude in the distal direction. As the needle cover 18B moves in the proximal direction, the first bacteria-shielding cover 200 moves relatively from the first cover distal portion 208 toward the first cover base end 210, and the first cover distal portion 208 is folded and contracted in the axial direction toward the first cover base end 210. The first bacteria-shielding cover 200 abuts against the receiving portion 218 of the needle cover 18B and is folded in the proximal direction so as to overlap in the axial direction.
[0160] When the first needle 112 has completed puncturing the skin S, the entire area of the first bacteria-shielding cover 200 between the base 208a and the first cover base end 210 is folded in the axial direction.
[0161] When the drive unit 34 is actuated and the syringe unit 20A moves toward the distal end together with the plunger 30, the lid body 94 comes into contact with the second cover base end 214 of the second bacteria-shielding cover 202 as the syringe unit 20A moves, and then, as the syringe unit 20A moves further toward the distal end, the needle tip of the second needle 114 punctures and penetrates the second cover base end 214. When the needle tip of the second needle 114 punctures the lid body 94, the distal end of the syringe 68 and the second needle 114 are connected.
[0162] As shown in Figure 41, after the second needle portion 114 and the syringe 68 are connected, the syringe unit 20A moves further toward the tip, causing the end face of the lid body 94 to push the second cover base end portion 214 toward the tip, and the second bacteria-shielding cover 202 moves relative to the second cover base end portion 214 toward the second cover tip end portion 212, and the second cover base end portion 214 is folded and contracted in the axial direction toward the second cover tip end portion 212 (see Figure 42).
[0163] The second bacteria-shielding cover 202 comes into contact with the base end of the second annular projection 206 and is folded over in the axial direction toward the tip end so as to overlap.
[0164] When the tip of the syringe unit 20A abuts against the support portion 124 of the needle hub 24B and the connection between the double-ended needle 22 and the syringe 68 is completed, the portion between the second cover tip portion 212 and the second cover base end portion 214 of the second antibacterial cover 202 is folded in the axial direction.
[0165] As described above, in the drug solution administration system 10B, the first needle portion 112 and the second needle portion 114 of the double-ended needle 22 are covered by the first bacteria-shielding cover 200 and the second bacteria-shielding cover 202, respectively, so that the double-ended needle 22 can be sterilized before assembling the drug solution administration device 12B. On the other hand, the syringe 68 can be sterilized by a sterilization method different from that for the double-ended needle 22 before assembling the drug solution administration device 12B. Therefore, a sterilization method appropriate for each of the double-ended needle 22 and the syringe 68 can be selected, so that a mismatch between the sterilization methods for the double-ended needle 22 and the syringe 68 can be avoided.
[0166] Therefore, it is possible to suitably suppress deterioration of the functionality of the syringe 68 and the double-ended needle 22 due to the sterilization process. By sterilizing the inside of the packaging container 14 containing the drug solution administration device 12B by the third sterilization method using sterile water W, it is also possible to ensure sterility between the lid 94 of the syringe 68 and the double-ended needle 22.
[0167] Since the drug solution administration system 10B can be sterilized without using large-scale sterile environment equipment that requires considerable installation and maintenance costs, the sterility of the entire drug solution administration device 12B can be ensured inexpensively until just before the user uses it.
[0168] By performing electron beam sterilization or radiation sterilization on the double-ended needle 22 (needle unit 26B) equipped with the first and second antibacterial covers 200, 202, it is possible to avoid thermal effects on the support part 124 of the needle hub 24B, which supports the double-ended needle 22 by adhesive or the like.
[0169] By subjecting the syringe 68, whose chamber 72 is filled with the liquid medicine M, to autoclave sterilization using high-pressure steam, it is possible to prevent the liquid medicine M from being denatured.
[0170] Sterile water W is dripped into container body 178 of packaging container 14, and the sterilized water W is evaporated in internal space 14a of container body 178, thereby creating a sterile atmosphere throughout container body 178. Therefore, the sterility of the entire medicinal solution administration device 12B can be ensured until sealing film 180 is peeled off from container body 178 and packaging container 14 is opened.
[0171] By using hydrogen peroxide water as the sterilizing water W, when the medicinal solution administration system 10B is left in an environment above room temperature, the hydrogen peroxide water can be vaporized in the internal space 14a of the packaging container 14 and fill the packaging container 14. The filled hydrogen peroxide gas can suitably sterilize the inside and outside surfaces of the medicinal solution administration device 12B.
[0172] Next, a chemical liquid administration system 10C will be described with reference to Figures 45 to 48. Note that the same components as those in the chemical liquid administration systems 10A and 10B are given the same reference numerals, and detailed description thereof will be omitted.
[0173] A chemical solution administration system 10C shown in FIG. 45 includes a chemical solution administration device 12C and a packaging container 14 having a sterilized internal space 14a in which the chemical solution administration device 12C is housed.
[0174] The needle unit 26C of the drug solution administration device 12C includes a needle hub 24C, a first bacteria-shielding cover 300 attached to the first needle portion 112 of the double-ended needle 22 supported by the needle hub 24C, and a second bacteria-shielding cover 302 attached to the second needle portion 114 of the double-ended needle 22, and the first and second bacteria-shielding covers 300, 302 are each formed in a cylindrical shape from an elastic material such as silicone rubber, butyl rubber, elastomer, etc. In the double-ended needle 22, a bacteria-shielding cover may be attached only to the first needle portion 112 that punctures the user's skin S.
[0175] The needle hub 24C has a first accommodating portion 304 and a first annular protrusion 306 arranged on the distal side of the support portion 124, and a second accommodating portion 308 and a second annular protrusion 310 arranged on the proximal side of the support portion 124.
[0176] The first accommodating portion 304 is a recess that can accommodate the first bellows portion 316 when the first bellows portion 316 of the first bacteria-shielding cover 300 is folded. The first accommodating portion 304 opens toward the tip (in the direction of arrow B).
[0177] The first annular protrusion 306 surrounds the first needle portion 112 and protrudes from the support portion 124 toward the distal end (direction of arrow B), and a first cover base end portion 314 of the first bacteria-shielding cover 300, which will be described later, is held on its outer periphery. The first storage portion 304 is disposed inside the first annular protrusion 306.
[0178] The second accommodating portion 308 is a recess that can accommodate the second bellows portion 324 when the second bellows portion 324 of the second bacteria-shielding cover 302 is folded. The second accommodating portion 308 opens toward the base end (the direction of arrow A).
[0179] The second annular protrusion 310 surrounds the second needle portion 114 and protrudes from the support portion 124 in the proximal direction (the direction of arrow A), and a second cover tip portion 320 of the second bacteria-shielding cover 302, which will be described later, is held on its outer periphery. A second storage portion 308 is disposed inside the second annular protrusion 310.
[0180] In the initial state before the puncture operation shown in Figures 45 and 46A is performed, the first bacteria-shielding cover 300 comprises a first cover tip portion 312 that covers the tip portion of the first needle portion 112, a first cover base end portion 314 that is connected to the first annular protrusion 306 of the needle hub 24C, and a first bellows portion 316 that is provided between the first cover tip portion 312 and the first cover base end portion 314.
[0181] The first cover distal end portion 312 has a smaller diameter than the first cover proximal end portion 314. The first cover proximal end portion 314 is open and engages with the outer periphery of the first annular protrusion 306 of the needle hub 24C and is held by the first annular protrusion 306.
[0182] 46A , first bellows portion 316 is formed in a truncated cone shape, and has a plurality of first folds 318 that are provided along the axial direction of first bacteria-shielding cover 300 and are recessed in the radial direction perpendicular to the axial direction. First bellows portion 316 can be folded in the radial direction via the plurality of first folds 318.
[0183] The second bacteria-shielding cover 302 comprises a second cover tip portion 320 connected to the second annular protrusion 310 of the needle hub 24C, a second cover base end portion 322 that covers the base end portion (needle tip) of the second needle portion 114 in the initial state before the puncture operation shown in Figures 45 and 46B is performed, and a second bellows portion 324 provided between the second cover tip portion 320 and the second cover base end portion 322.
[0184] The second cover distal end portion 320 is open and engages with the outer periphery of the second annular protrusion 310 of the needle hub 24C and is held by the second annular protrusion 310. The second cover proximal end portion 322 has a smaller diameter than the second cover distal end portion 320. In the initial state before puncturing, the second cover proximal end portion 322 is inserted into and held in the insertion hole 92 of the cap 78.
[0185] 46B , second bellows portion 324 is formed in a truncated cone shape, and has a plurality of second folds 326 that are provided along the axial direction of second bacteria-shielding cover 302 and are recessed in the radial direction perpendicular to the axial direction. Second bellows portion 324 can be folded in the radial direction via the plurality of second folds 326.
[0186] Next, the operation of the chemical liquid administration device 12C of the chemical liquid administration system 10C will be described. Note that detailed explanations of the same operations as those of the chemical liquid administration devices 12A and 12B will be omitted.
[0187] From the initial state before the puncture operation shown in Figure 45, when the user presses the tip of the needle cover 18B against the skin S and the needle cover 18B moves relative to the housing 16 in the proximal direction, as the needle cover 18B moves in the proximal direction, the first cover tip portion 312 of the first antibacterial cover 300 abuts against the receiving portion 218 of the needle cover 18B, and then the first cover tip portion 312 is pushed up in the proximal direction (direction of arrow A) together with the needle cover 18B.
[0188] 47 , the movement of the needle cover 18B toward the proximal end causes the first cover distal end portion 312 to move relatively toward the first cover proximal end portion 314, and the first bellows portion 316 is folded radially starting from the multiple first folds 318. At this time, because the first bellows portion 316 has a truncated cone shape, the first bacteria-shielding cover 300 can be folded smoothly, and is folded so that the first cover distal end portion 312 is radially inward relative to the first cover proximal end portion 314.
[0189] When the tip of the first needle portion 112 is inserted into the first cover tip portion 312, the first needle portion 112 protrudes outside the first cover tip portion 312 and protrudes from the tip of the needle cover 18B through the tip opening 64 to puncture the skin S.
[0190] 47 , as the needle cover 18B is further moved toward the proximal end, the first bellows portions 316 are folded radially inward in order on the radially inner side of the first cover base end portion 314, and the folded first bellows portions 316 are accommodated in the first accommodation portion 304 so as to overlap radially. As the first bellows portions 316 are folded radially, the first bacteria-shielding cover 300 contracts in the axial direction so that the first cover tip portion 312 approaches the first cover base end portion 314.
[0191] When the puncture by the first needle 112 is completed, the first bellows portion 316 of the first bacteria-shielding cover 300 is folded in its entirety in the radial direction and accommodated in the first accommodation portion 304 .
[0192] When the drive unit 34 is actuated to move the syringe unit 20A together with the plunger 30 toward the distal end, the movement of the syringe unit 20A causes the insertion hole 92 of the cap 78 to abut against the second cover base end 322 of the second bacteria-shielding cover 302, and then, as the syringe unit 20A moves further toward the distal end, the needle tip of the second needle 114 punctures and passes through the second cover base end 322. The needle tip of the second needle 114 punctures the lid 94, connecting the distal end of the syringe 68 and the second needle 114.
[0193] After the second needle portion 114 and the syringe 68 are connected, the syringe unit 20A moves further in the distal direction, whereby the cap 78 pushes the second cover base end portion 322 in the distal direction, and the second cover base end portion 322 moves relatively toward the second cover distal end portion 320, and accordingly, the second bellows portion 324 of the second bacteria-shielding cover 302 is folded in the radial direction starting from the second fold 326. At this time, because the second bellows portion 324 has a truncated cone shape, the second bacteria-shielding cover 302 can be folded smoothly, and is folded so that the second cover base end portion 322 is radially inward relative to the second cover distal end portion 320.
[0194] 48 , as syringe unit 20A moves further toward the tip, second bellows portion 324 is folded radially inward in order on the radially inner side of second cover tip portion 320, and folded second bellows portion 324 is accommodated in second accommodation portion 308 so as to overlap radially. As second bellows portion 324 is folded radially, second bacteria-shielding cover 302 contracts in the axial direction so that second cover base end portion 322 approaches second cover tip portion 320.
[0195] When the connection between the second needle portion 114 of the double-ended needle 22 and the syringe 68 is completed, the second bellows portion 324 of the second bacteria-shielding cover 302 is folded in its entirety in the radial direction and accommodated in the second accommodation portion 308 .
[0196] The above-described chemical solution administration system 10C may be sterilized by the first to third sterilization methods carried out for the chemical solution administration system 10B.
[0197] The needle body of the drug solution administration device 12C to which the bacteria-shielding cover is attached is not limited to the double-ended needle 22 having the first and second needle portions 112, 114. The needle body may be a single-ended needle that is connected to the tip of the syringe 68 in advance.
[0198] The first bacteria-shielding cover 300 may have a first cover base end 314 formed with a smaller diameter than the first cover tip end 312. The second bacteria-shielding cover 302 may have a second cover tip end 320 formed with a smaller diameter than the second cover base end 322. In this case as well, when the first and second bacteria-shielding covers 300, 302 are folded in the axial direction, the first and second bellows portions 316, 324 can be folded in the radial direction. At this time, the first cover tip end 312 is housed radially outside the first cover base end 314, and the second cover base end 322 is housed radially outside the second cover tip end 320.
[0199] As described above, the drug solution administration device 12C of the drug solution administration system 10C has first and second bacteria-shielding covers 300, 302 attached to the first and second needle portions 112, 114 of the double-ended needle 22, and the first bacteria-shielding cover 300 includes a first cover base end portion 314 connected to the needle hub 24C, a first cover distal end portion 312 having a different diameter from the first cover base end portion 314 and covering the distal end portion of the first needle portion 112 in an initial state, and a first bellows portion 316 disposed between the first cover distal end portion 312 and the first cover base end portion 314. The second bacteria-shielding cover 302 includes a second cover distal end portion 320 connected to the needle hub 24C, a second cover base end portion 322 having a different diameter from the second cover base end portion 322 and covering the distal end portion of the second needle portion 114 in an initial state, and a second bellows portion 324 disposed between the second cover distal end portion 320 and the second cover base end portion 322.
[0200] When the second needle portion 114 of the double-ended needle 22 punctures the user's skin S, the first cover distal end portion 312 and the first cover proximal end portion 314 of the first bacteria-shielding cover 300 move relative to each other in the axial direction, causing the first bellows portion 316 to fold radially. Therefore, the first and second bacteria-shielding covers 300, 302, which are foldable in the radial direction, can have a shorter axial dimension when folded compared to conventional bacteria-shielding covers that fold axially.
[0201] As a result, both the first antibacterial cover 300 and the second antibacterial cover 302 that cover the double-ended needle 22 can be folded radially, so that the axial dimension of the drug solution administration device 12C having the double-ended needle 22 can be effectively reduced in size.
[0202] By making the first bellows portion 316 of the first bacteria-shielding cover 300 and the second bellows portion 324 of the second bacteria-shielding cover 302 truncated cone shaped, the first and second bacteria-shielding covers 300, 302 can be folded smoothly, thereby suppressing an increase in puncture resistance during puncture caused by providing the double-ended needle 22 with the first and second bacteria-shielding covers 300, 302.
[0203] When the first and second bellows portions 316, 324 are folded, the first and second bellows portions 316, 324 can be accommodated in the first and second accommodating portions 304, 308 provided inside the first cover base end portion 314 and the second cover tip end portion 320, respectively, thereby reducing the axial thickness of the needle hub 24C near the support portion 124 where the first and second bellows portions 316, 324 are folded. This allows the axial dimension of the drug solution administration device 12C including the needle hub 24C to be reduced.
[0204] In the first bacteria-shielding cover 300, by making the first cover distal end 312 have a smaller diameter than the first cover proximal end 314, when the first bacteria-shielding cover 300 is folded, the first cover distal end 312 can be positioned radially inward of the first cover proximal end 314. Therefore, compared to when the first cover proximal end 314 has a smaller diameter than the first cover distal end 312, the outer diameter of the first bacteria-shielding cover 300 can be made smaller, which can contribute to the miniaturization of the drug solution administration device 12C.
[0205] By making the second cover base end 322 of the second bacteria-shielding cover 302 smaller in diameter than the second cover tip end 320, when the second bacteria-shielding cover 302 is folded, the second cover base end 322 can be positioned radially inside the second cover tip end 320. Therefore, compared to when the second cover tip end 320 has a smaller diameter than the second cover base end 322, the outer diameter of the second bacteria-shielding cover 302 can be made smaller, which can contribute to the miniaturization of the drug solution administration device 12C.
[0206] By providing the first bellows portion 316 with a plurality of radially recessed first folds 318, when the first bacteria-shielding cover 300 is folded in the axial direction, the first cover tip portion 312 and the first cover base portion 314 can be folded so as to be radially arranged starting from the plurality of first folds 318. By providing the second bellows portion 324 with a plurality of radially recessed second folds 326, when the second bacteria-shielding cover 302 is folded in the axial direction, the second cover tip portion 320 and the second cover base portion 322 can be folded so as to be radially arranged starting from the plurality of second folds 326.
[0207] Next, a chemical solution administration system 10D will be described with reference to Figures 49 to 55C. Note that the same components as those in the chemical solution administration systems 10A, 10B, and 10C are given the same reference numerals, and detailed description thereof will be omitted.
[0208] A medicinal solution administration system 10D shown in FIG. 49 includes a medicinal solution administration device 12D and a packaging container 14 in which the medicinal solution administration device 12D is housed.
[0209] The drug solution administration device 12D includes a speed reduction mechanism 400 that reduces the speed of movement of the syringe unit 20D toward the distal end during the puncture operation. The speed reduction mechanism 400 reduces the speed of movement of the syringe unit 20D toward the distal end after the second needle portion 114 of the double-ended needle 22 begins to pierce the cover 94 of the syringe unit 20D and before the connection between the distal end of the syringe unit 20D and the second needle portion 114 is completed.
[0210] As shown in Figures 49 to 51, the reduction mechanism 400 has a reduction section 402 arranged on the outer peripheral surface of the holder tip tube portion 100 of the syringe holder 70D, and multiple reduction sections 402 are provided along the circumferential direction of the holder tip tube portion 100.
[0211] The speed reducer 402 is disposed at the base end of the holder tip tube portion 100 and is an inclined protrusion 404 provided at the base end of the first guide rib 134 .
[0212] 51 to 53, the inclined protrusions 404 protrude outward from the first guide rib 134 in a direction perpendicular to the first guide rib 134 and are inclined so that the protruding height from the first guide rib 134 increases toward the proximal end (the direction of arrow A) (see FIG. 53). When the syringe unit 20D moves toward the distal end and the first guide ribs 134 are inserted into the first guide grooves 142, the inclined protrusions 404 engage with the inner surfaces 142a of the first guide grooves 142, increasing the insertion length of the first guide ribs 134 into the first guide grooves 142. The inclined protrusions 404 gradually increase the sliding resistance between the syringe holder 70D and the needle hub 24A.
[0213] The inclined protrusion 404 of the speed reducer 402 may be provided on the inner surface 142a of the first guide groove 142 into which the first guide rib 134 is inserted, instead of on the first guide rib 134. In this case, the inclined protrusion 404 is disposed at the tip of the first guide groove 142. That is, the speed reducer 402 may be provided at at least one of the base end of the outer peripheral surface of the holder tip tube portion 100 of the syringe holder 70D and the tip of the inner peripheral surface of the guide tube portion 118 of the needle hub 24A.
[0214] 55A , during the puncture operation of the medicinal solution administration device 12D, the syringe unit 20D moves toward the distal end together with the plunger 30 due to the elastic force of the injection spring 146, and the distal end of the first guide rib 134 of the syringe holder 70D begins to be inserted into the first guide groove 142 from the proximal end of the first guide groove 142 of the needle hub 24A. At this time, the inclined protrusion 404 has not yet been inserted into the first guide groove 142.
[0215] 55B , after syringe unit 20D moves toward the distal end and second needle portion 114 of double-ended needle 22 begins to pierce the distal end (lid body 94) of syringe 68, inclined protrusion 404 begins to contact inner surface 142a of first guide groove 142. This causes the sliding resistance between inclined protrusion 404 and first guide groove 142 to gradually increase.
[0216] Therefore, before the connection between the tip of syringe unit 20D and second needle portion 114 is completed, the speed of movement of syringe unit 20D toward the tip is gradually reduced by deceleration unit 402. Syringe unit 20D, whose movement speed has been reduced, moves further toward the tip, and as shown in Fig. 55C, the tip of syringe unit 20D abuts against support portion 124 of needle hub 24A, which serves as a stopper, thereby stopping the movement and completing the connection between syringe unit 20D and second needle portion 114.
[0217] That is, the speed reduction mechanism 400 reduces the speed of movement of the syringe unit 20D toward the tip from the time when the second needle 114 begins to pierce the tip of the syringe 68 shown in FIG. 55B until the connection between the second needle 114 and the tip of the syringe 68 is completed as shown in FIG. 55C.
[0218] The speed reducer 402 may be disposed directly on the outer peripheral surface of the holder tip tube portion 100 where the first guide rib 134 is provided, or may be disposed directly on the inner peripheral surface of the guide tube portion 118 where the first guide groove 142 is provided. In other words, the speed reducer 402 may be disposed on at least one of the base end of the outer peripheral surface of the holder tip tube portion 100 and the tip end of the inner peripheral surface of the guide tube portion 118.
[0219] As described above, when syringe unit 20D moves toward the tip during a puncture operation by medicinal solution administration device 12D, the speed of movement of syringe unit 20D is reduced by speed reduction mechanism 400, thereby suppressing the impact that syringe unit 20D receives when the tip of syringe unit 20D abuts against needle hub 24A and stops. As a result, damage to syringe unit 20D due to impact can be prevented.
[0220] The speed reduction mechanism 400 increases the sliding resistance of the syringe unit 20D while the syringe unit 20D is moving toward the distal end, thereby enabling the speed reduction mechanism 400 to suitably reduce the moving speed of the syringe unit 20D with a simple configuration.
[0221] The speed reducing mechanism 400 has a speed reducing portion 402 provided on the outer peripheral surface of the holder tip tube portion 100 of the syringe holder 70D. The speed reducing portion 402 protrudes from the outer peripheral surface of the holder tip tube portion 100 and is formed so as to be able to contact the inner peripheral surface of the guide tube portion 118 of the needle hub 24A into which the holder tip tube portion 100 is inserted. As a result, when the syringe holder 70D moves distally and the holder tip tube portion 100 is inserted into the guide tube portion 118 of the needle hub 24A, the syringe holder 70D and the needle hub 24A come into contact via the speed reducing portion 402, thereby increasing the sliding resistance between the syringe holder 70D and the needle hub 24A. As a result, the speed at which the syringe unit 20D moves distally can be effectively reduced.
[0222] By providing the speed reducer 402 in the holder tip tube portion 100 provided at the tip of the syringe holder 70D, it is possible to reduce the movement speed of the syringe unit 20D including the syringe holder 70D before the connection between the tip of the syringe 68 and the second needle portion 114 of the double-ended needle 22 is completed. Therefore, it is possible to minimize the increase in the time required to connect the syringe unit 20D and the double-ended needle 22 due to the provision of the speed reducer 402.
[0223] Since the clearance between the first guide rib 134 and the first guide groove 142 is smaller than the clearance between the syringe holder 70D and other components including the needle hub 24A, by arranging the speed reducer 402 on the first guide rib 134, the syringe holder 70D and the needle hub 24A can be brought into more reliable contact with each other via the speed reducer 402, thereby reducing the movement speed.
[0224] By making the deceleration section 402 an inclined protrusion 404 provided on the first guide rib 134, as the syringe unit 20D moves toward the tip, the inclined protrusion 404 gradually slides against the inner surface 142a of the first guide groove 142 of the needle hub 24A, gradually increasing the sliding resistance between the syringe holder 70D and the needle hub 24A, thereby gradually reducing the movement speed of the syringe unit 20D.
[0225] By providing a plurality of deceleration sections 402 along the circumferential direction of the syringe holder 70D, it is possible to stably decelerate the moving speed of the syringe 68 when it moves toward the distal end.
[0226] Next, a chemical solution administration system 10E will be described with reference to Figures 56 to 63. Note that the same components as those in the chemical solution administration systems 10A, 10B, 10C, and 10D are given the same reference numerals, and detailed description thereof will be omitted.
[0227] A medicinal liquid administration system 10E shown in FIG. 56 includes a medicinal liquid administration device 12E and a packaging container 14 in which the medicinal liquid administration device 12E is housed.
[0228] A chemical solution administration device 12E shown in FIG. 57 includes a vibration generating mechanism 500 that can impart vibrations to a syringe unit 20E when the syringe unit 20E moves toward the distal end along a housing 16.
[0229] The vibration generating mechanism 500 has a first vibration generating part 502 provided on the outer peripheral surface of the syringe unit 20E, and a second vibration generating part 504 formed on the needle hub 24E fixed inside the housing 16 and capable of coming into contact with the first vibration generating part 502 when the syringe unit 20E moves toward the tip.
[0230] 57 and 58 , the first vibration generating unit 502 is disposed on the outer peripheral surface of the holder tip tube portion 100, which is the tip portion of the syringe holder 70E. The first vibration generating unit 502 has a first protrusion 506 that protrudes radially outward from the outer peripheral surface of the holder tip tube portion 100. Note that in a drug solution administration device that does not include the syringe holder 70E and that only includes the syringe 68, the first vibration generating unit 502 is provided on the outer peripheral surface of the syringe 68.
[0231] A plurality of first protrusions 506 are provided along the movement direction (direction of arrows A and B) of syringe unit 20E, with each first protrusion 506 spaced apart in the movement direction. A pair of first protrusions 506 are arranged in the circumferential direction of syringe unit 20E. The cross-sectional shape of each first protrusion 506 is a triangular shape tapering radially outward from the outer circumferential surface of syringe 68. First protrusion 506 may be annular and extend along the circumferential direction of syringe unit 20E.
[0232] 57 , the second vibration generating unit 504 is provided on the inner circumferential surface of the base end of the guide tube portion 118 of the needle hub 24E, and has a second protrusion 508 that protrudes radially inward from the inner circumferential surface. The second protrusion 508 is positioned opposite the first protrusion 506. The cross-sectional shape of the second protrusion 508 is a triangle that tapers radially inward from the inner circumferential surface of the needle hub 24E. When viewed in the axial direction of the syringe 68, the first protrusion 506 and the second protrusion 508 are positioned to overlap.
[0233] The second protrusion 508 may be one or more provided along the movement direction of the syringe unit 20E. When a plurality of second protrusions 508 are arranged, the second protrusions 508 are spaced apart from one another in the axial direction of the needle hub 24E.
[0234] In the process of the puncture operation of the medicinal solution administration device 12E, after the syringe unit 20E moves distally together with the plunger 30 from the initial state shown in Fig. 57 due to the elastic force of the injection spring 146, the distal end of the holder distal end tube portion 100 is inserted from the proximal end of the guide tube portion 118 of the needle hub 24E, and before the second needle portion 114 is connected to the distal end (lid 94) of the syringe 68, as shown in Fig. 59, the first protrusion 506 arranged furthest distally among the multiple first protrusions 506 comes into contact with the second protrusion 508. Vibrations are generated as the first protrusion 506 comes into contact with the second protrusion 508, and the vibrations are applied to the vicinity of the nozzle 82 at the distal end of the syringe 68.
[0235] Since the drug solution administration device 12E is normally used with its tip facing downward or diagonally downward, the vibrations applied by the vibration generating mechanism 500 to the vicinity of the nozzle 82 of the syringe 68 cause the air bubbles contained in the drug solution M in the chamber 72 of the barrel 74 to separate from the inner wall of the barrel 74, and the buoyancy of the air bubbles causes them to move toward the gasket 76 located above (see Figure 60).
[0236] As shown in Figure 61, as the syringe unit 20E moves toward the tip, the multiple first protrusions 506 successively come into contact with the second protrusions 508, causing multiple vibrations to be applied to the vicinity of the nozzle 82 of the syringe 68, thereby reliably separating the air bubbles contained in the medicinal solution M from the inner wall of the barrel 74 and moving the air bubbles toward the gasket 76.
[0237] 62, after the first protrusion 506, which is disposed most proximally, passes the second protrusion 508 in the distal direction, the distal end of the syringe unit 20E comes into contact with the support portion 124 of the needle hub 24E, thereby stopping the movement of the syringe unit 20E. The connection between the syringe unit 20E and the second needle portion 114 is completed (see FIG. 63).
[0238] The resilient force of injection spring 146 causes plunger 30 to move further in the distal direction, and plunger 30 pushes gasket 76 in the distal direction, thereby administering medicinal solution M subcutaneously to the user through lumens 112a, 114a of double-ended needle 22. At this time, as shown in Figures 62 and 63, the vibrations generated by vibration generating mechanism 500 cause air bubbles in medicinal solution M to move toward gasket 76 (in the direction of arrow A), which is on the opposite side of double-ended needle 22, making it possible to administer only medicinal solution M that does not contain air bubbles through double-ended needle 22.
[0239] Furthermore, when administering a fixed amount of medicinal liquid M using a plunger 30a having a convex portion 196 as shown in Figure 34, the vibration generating mechanism 500 can be used to move the air bubbles toward the base end, which is effective in accurately administering the desired amount of medicinal liquid M.
[0240] The needle of the drug solution administration device 12E having the vibration generating mechanism 500 is not limited to the double-ended needle 22 having the first and second needle portions 112, 114 and connected to the tip as the syringe unit 20E moves. The needle may be, for example, a single-ended needle previously connected to the tip of the syringe 68.
[0241] As described above, medicinal solution administration device 12E includes vibration generating mechanism 500 that can impart vibrations to syringe unit 20E when syringe unit 20E moves toward the distal end along housing 16 during a puncture operation. By applying vibrations to syringe unit 20E using vibration generating mechanism 500, air bubbles contained in medicinal solution M filled in barrel 74 of syringe 68 can be moved away from the inner wall of barrel 74 and, due to the buoyancy of the air bubbles, moved toward gasket 76 located above. As a result, when medicinal solution M is administered subcutaneously to a user through double-ended needle 22, the amount of air bubbles contained in the administered medicinal solution M can be reduced, making it possible to administer a predetermined amount of medicinal solution M subcutaneously with high accuracy.
[0242] The vibration generating mechanism 500 comprises a first vibration generating part 502 provided on the outer peripheral surface of the syringe unit 20E, and a second vibration generating part 504 provided on the inner peripheral surface of the needle hub 24E and capable of coming into contact with the first vibration generating part 502 when the syringe unit 20E moves toward the tip. This makes it possible to generate vibrations simply and reliably by utilizing the movement of the syringe unit 20E toward the tip, without providing a complex mechanism such as an actuator.
[0243] By providing multiple copies of at least one of the first vibration generating unit 502 and the second vibration generating unit 504, vibrations can be generated multiple times when the syringe unit 20E moves toward the tip, making it possible to more reliably move air bubbles contained in the medicinal liquid M upward within the barrel 74.
[0244] The first vibration generating unit 502 has a first protrusion 506 that protrudes radially outward from the outer peripheral surface of the holder tip tube portion 100 of the syringe holder 70E, and the second vibration generating unit 504 has a second protrusion 508 that protrudes radially inward from the inner peripheral surface of the guide tube portion 118 of the needle hub 24E. Therefore, when the syringe unit 20E is moved toward the tip, the first protrusion 506 and the second protrusion 508 come into contact with each other, thereby applying intermittent vibrations to the syringe unit 20E. Therefore, air bubbles contained in the medicinal solution M and adhering to the inner wall of the barrel 74 can be reliably separated from the inner wall and moved upward.
[0245] By placing the first vibration generating unit 502 in the holder tip tube portion 100, which is the tip of the syringe holder 70E, air bubbles in the medicinal solution M, which tend to accumulate at the tip within the barrel 74 of the syringe 68, can be reliably moved away from the inner wall of the barrel 74 and moved from the tip of the syringe 68 toward the base end.
[0246] The above embodiment can be summarized as follows.
[0247] The above embodiment includes a housing (16) formed in a hollow cylindrical shape, a syringe (68) housed in the housing, the syringe (68) having a barrel (74) with a chamber (72) filled with a medicinal liquid (M) and a gasket (76) capable of sliding liquid-tightly inside the barrel, a plunger (30, 30a) biased in a distal direction by a biasing member (146), a double-ended needle (22) having a first needle portion (112) protruding in the distal direction to puncture a target, and a second needle portion (114) protruding in a proximal direction toward the syringe, the double-ended needle (22) being disposed inside the housing, the lumen (112a) of the first needle portion communicating with the lumen (114a) of the second needle portion, and a hollow cylindrical needle cover (18A) having a tip opening (64), at least a portion of which is provided inside the housing, covering the first needle portion in an initial state and being pressed against the object to be punctured, thereby displacing relative to the housing in the base end direction and causing the first needle portion to protrude from the tip opening; and a locking mechanism (32) that prevents the plunger from moving in the tip direction in an initial state, wherein as the needle cover moves in the base end direction, the locking mechanism releases the prevention of movement of the plunger, and the plunger, biased by the biasing member, pushes the gasket in the tip direction, causing the syringe to move in the tip direction, the second needle portion punctures the tip of the syringe, and the second needle portion communicates with the drug chamber of the barrel, and as the second needle portion punctures the tip of the syringe, the gasket moves in the tip direction relative to the barrel.
[0248] The syringe includes a needle unit (26A) having the double-ended needle and a needle hub (24A) that holds the double-ended needle, wherein the first needle portion protrudes toward the tip end relative to a support portion (124) of the needle hub, and the second needle portion protrudes toward the base end relative to the support portion, and when the syringe moves toward the tip end, the tip of the syringe abuts against and is locked on the support portion.
[0249] The syringe has a syringe holder (70A) that is arranged on the outer periphery of the syringe to hold the syringe and is movably arranged inside the housing, and the syringe holder is guided by the housing so as to be movable toward the tip end.
[0250] The syringe holder has an engagement portion (46b) that engages with the housing in the initial state, and the force of the biasing member causes the plunger to push the gasket toward the tip, thereby releasing the engagement of the engagement portion with the housing.
[0251] The locking mechanism comprises a locking member (152) arranged inside the housing so as to be displaceable in the axial direction, an elastic member (154) that urges the locking member toward the distal end, and a locking body (156) that engages with the plunger in the initial state to prevent the plunger from moving toward the distal end, and the engagement with the plunger is released when the locking member moves toward the proximal end as the needle cover moves toward the proximal end.
[0252] The locking member is formed in a cylindrical shape surrounding the plunger (30), the locking body has an engaging arm (170) that is elastically deformable in the radial direction, the engaging arm engages with the outer periphery of the plunger in the initial state, and the engaging arm is prevented from deforming radially outward by the locking member, and as the locking member moves toward the base end, the engaging arm elastically deforms radially outward, and the engagement between the engaging arm and the plunger is released.
[0253] When the locking member moves in the distal direction, the locking member comes into contact with the engaging arms of the lock body, causing the engaging arms to elastically deform radially inward, thereby enabling the locking member to move in the distal direction.
[0254] The present invention is not limited to the above disclosure, and various configurations can be adopted without departing from the gist of the present invention.
Claims
1. A housing formed in a hollow cylindrical shape; a syringe housed in the housing, the syringe having a barrel having a chamber filled with a liquid and a gasket capable of sliding liquid-tightly inside the barrel; A plunger that is biased in a distal direction by a biasing member; a double-ended needle having a first needle portion that protrudes in the distal direction and punctures the target, and a second needle portion that protrudes in the proximal direction toward the syringe, the double-ended needle being disposed inside the housing, the inner cavity of the first needle portion communicating with the inner cavity of the second needle portion; a hollow cylindrical needle cover having a tip opening, at least a portion of which is provided inside the housing, covering the first needle portion in an initial state and being displaced relative to the housing in the base end direction when pressed against the object to be punctured, causing the first needle portion to protrude from the tip opening; a lock mechanism that prevents the plunger from moving toward the distal end in the initial state; A drug solution administration device comprising: As the needle cover moves in the base end direction, the locking mechanism releases the plunger from its movement prevention state, and the plunger, biased by the biasing member, pushes the gasket in the tip end direction, causing the syringe to move in the tip end direction, and the second needle portion is pierced by the tip of the syringe, thereby connecting the second needle portion to the chamber of the barrel. A drug solution administration device, wherein the gasket moves toward the tip relative to the barrel as the second needle portion punctures the tip of the syringe.
2. 2. The drug solution administration device according to claim 1, a needle unit including the double-ended needle and a needle hub for holding the double-ended needle; The first needle portion protrudes toward the distal end direction relative to a support portion of the needle hub, and the second needle portion protrudes toward the proximal end direction relative to the support portion, When the syringe moves in the tip direction, the tip of the syringe abuts against the support portion and is locked in place.
3. 3. The drug solution administration device according to claim 1, a syringe holder disposed on an outer periphery of the syringe to hold the syringe and movably disposed inside the housing; The syringe holder is movably guided toward the tip end direction by the housing.
4. 4. The drug solution administration device according to claim 3, the syringe holder has an engagement portion that engages with the housing in the initial state, A medicinal liquid administration device in which the plunger pushes the gasket toward the tip direction due to the biasing force of the biasing member, thereby releasing the engagement of the engagement portion with the housing.
5. 3. The drug solution administration device according to claim 1, The locking mechanism includes a locking member disposed inside the housing so as to be displaceable in an axial direction; an elastic member that biases the locking member in the distal direction; a lock body that engages with the plunger in the initial state to prevent the plunger from moving in the distal end direction; Equipped with The locking member moves in the base end direction as the needle cover moves in the base end direction, thereby releasing the engagement with the plunger.
6. 6. The drug solution administration device according to claim 5, The locking member is formed in a cylindrical shape surrounding the plunger, The lock body has an engagement arm that is elastically deformable in a radial direction, In the initial state, the engagement arm engages with an outer periphery of the plunger, and the engagement arm is prevented from being deformed radially outward by the lock member, As the locking member moves in the base end direction, the engagement arm elastically deforms radially outward, thereby releasing the engagement between the engagement arm and the plunger.
7. 7. The drug solution administration device according to claim 6, When the locking member moves in the tip direction, the locking member comes into contact with the engagement arm of the lock body, causing the engagement arm to elastically deform radially inward, thereby enabling the locking member to move in the tip direction.
